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Riassunto 
Mutazioni nel gene legato al cromosoma X, MeCP2 (Methyl CpG-binding 
protein) sono presenti in circa l’80% dei pazienti affetti da Sindrome di Rett, una 
delle più comuni cause di ritardo mentale nelle bambine e per cui ancora oggi non 
esistono efficaci trattamenti farmacologici. Un aspetto rilevante, ma ancora poco 
esplorato, nei pazienti con sindrome di Rett è la riduzione della circolazione 
periferica. 
Per investigare la relazione tra la perdita di MeCP2 e questo aspetto clinico 
abbiamo utilizzato per gli studi funzionali, farmacologici e comportamentali, topi 
mancanti del gene MeCP2, maschi (MeCP2
y/-
) e femmine (MeCP2
+/-
). Gli studi 
funzionali condotti su branche dissezionate delle arteriole dell’albero mesenterico 
montate su microcannule di vetro in un miografo a pressione, hanno mostrato una 
drammatica riduzione della reattività vascolare endotelio dipendente nei topi 
MeCP2
+/-
 rispetto ai controlli sani. Le arteriole preincubate con inibitori delle 
NOS o con acido ascorbico hanno rilevato una ridotta biodisponibilità di Ossido 
Nitrico (NO) e un aumento nelle specie reattive dell’ossigeno (ROS). Inoltre, 
l’animale Rett presenta bassi livelli di espressione sia dell’mRNA che del peptide 
eNOS nelle arteriole e alti livelli di stress ossidativo. Da un punto di vista 
comportamentale i topi knockout per MeCP2 mostrano comportamenti stereotipati 
e si osserva una riduzione del tempo di riposo. 
Il trattamento cronico delle femmine MeCP2
+/-
 con curcumina è in grado di 
ripristinare il normale fenotipo e di migliorare la sintomatologia comportamentale 
della Rett, diminuendo i caratteristici movimenti stereotipati e aumentando il 
tempo di riposo degli animali.  
Questi dati indicano che la mancanza del gene MeCP2 modifica la circolazione 
periferica alterando la reattività vascolare, riducendo i livelli di espressione di 
eNOS e di NO. Inoltre, i nostri risultati supportano sia dal punto di vista 
funzionale/molecolare che comportamentale l’utilizzo della curcumina nella 
terapia dei pazienti affetti da sindrome di Rett.  
 
 
  
 
Abstract  
Mutations in the coding sequence of the X-linked gene MeCP2 (Methyl CpG–
binding protein), are present in around 80% of patients with Rett Syndrome, a 
common cause of mental retardation in female and to date without any effective 
pharmacological treatment. A relevant, and so far unexplored feature of RTT 
patients is a marked reduction in peripheral circulation. 
To investigate the relationship between loss of MeCP2 and this clinical aspect, we 
used a MeCP2 null mouse model, male (MeCP2
y/-
) and female (MeCP2
+/-
), for 
functional, pharmacological and behavioural studies. The functional studies 
performed on dissected branches of mesenteric arterial tree mounted on glass 
microcannule in a pressurized myograph, demonstrated a dramatic endothelial-
dependent vascular reactivity impairment in MeCP2
+/-
 compared to control 
littermate. The mesenteric arteriole preincubation with NOS inhibitors or ascorbic 
acid indicate a decrease Nitric Oxide (NO) availability and the increased presence 
of Reactive Oxygen Species (ROS). Consistently, the RTT mouse model 
exhibited a decreased expression in both mRNA and peptide eNOS in the 
arterioles and a higher systemic oxidative level. MeCP2 knockout mice show 
stereotyped movements and less resting time when compared to control 
littermates. 
Chronic curcumin treatment of female MeCP2
+/-
 mice was able to reverse this 
vascular phenotype and ameliorate the mouse RTT behavioural symptomatology 
by decreasing stereotyped movements and by increasing resting time.  
These data indicate that in the absence of MeCP2 peripheral circulation is 
impaired by an altered vascular reactivity and decreased arteriolar eNOS 
expression and NO production. Further, they provide a physiological/molecular 
rational for the use of curcumin as a treatment to improve the health of RTT 
patients. 
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1.1Pervasive developmental disorders: an overview 
Pervasive developmental disorders (PDD), also called autism spectrum disorders, 
comprise a complex and heterogeneous group of pathological conditions 
characterized by abnormalities of brain development and function, appearing 
within the first three years of life. Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DMS-IV) identify as PDD five pathology: autism, Rett 
syndrome, childhood disintegrative disorder, Asperger disorder and PDD not 
otherwise specified under the spectrum of PDD (PDD-NOS) (American 
Psychiatric Association., 2000) (Figure 1).  
 
 
 
 
 
 
 
Figure 1: Pervasive Developmental Disorders (PDD). Current Classification 
in DMS-IV. 
 
Although the detailed causal mechanisms are not known, autism is likely to have 
multiple etiologies including genetic factors. Children with PDD share the 
following characteristics: 
i) impairments in social interaction;  
ii) inability to imaginative activity;  
iii) problems in verbal and nonverbal communication skills;  
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iv) stereotyped behaviors;  
v) cognitive deficits;  
vi) limited number of interests and activities.  
Children affected by PDD have difficult in talking, playing with other children, 
and relating to others, including their family. 
The incidence of these disorders has risen dramatically over the past two decades 
mainly because of the use of broader diagnostic criteria and the increased 
attention of the medical community (Levy et al, 2009) and is estimated 60-
70/10000 children. PDD is 4/5 times more frequently in boys, with the exception 
of Rett syndrome, which is found mainly in girls. Great interest exists in the 
elucidation of the causes and pathogenesis of autism. Although autism is 
recognized to be the common endpoint of neurological dysfunction of varying 
etiologies, common disease mechanisms may underlie the phenotypes shared by 
RTT and autism, and advances in understanding of RTT may also shed some light 
into the pathogenesis of autism. 
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1.2 Rett Syndrome 
Rett syndrome (RTT) is a neurological disorder that predominantly affects girls 
(Hagberg et al, 1985; Hagberg & Hagberg, 1997). It represents the second most 
common cause of mental retardation in females with an incidence of 1:10000 
(Percy, 2002). The disease has been described for the first time by the Austrian 
neurologist Andreas Rett in 1966, but the scientist community recognized the 
pathology only 17 years later when the Swedish neurologist Dr. B. Hagberg 
described 35 new cases of RTT (Hagberg et al, 1983).  
In 1954, the Viennese pediatrician Dr. Andreas Rett observed two girls in his 
waiting room displaying the same repetitive hand-washing motions. Looking at 
their clinical charts, he realized they shared similar clinical and developmental 
histories. Dr. Rett soon recognized that six other girls in his practice had similar 
behaviors, and reasoned that these girls must have the same disorder, which at that 
time was new to the medical field. In fact, their distinctive behavioral patterns 
indicated to him that this new condition was not a simple mental retardation 
syndrome, but rather a complex condition that affected several facets of neural 
function. Unfortunately, during the 1960’s in Europe the medical community was 
hesitant to recognize “new” conditions in the absence of a metabolic abnormality. 
This led Dr. Rett to examine several physiological parameters in his affected girls, 
where he found elevated ammonia content in blood. In 1966, Dr. Rett published 
his observations in a leading German medical journal, where he described the 
condition as one of cerebral atrophy and hyperammonia in girls, characterized by 
autistic behavior, dementia, and apraxia of gait (Rett, 1966). The condition stayed 
mostly unrecognized in the English language literature until 1983, when Bengt 
Hagberg described 35 patients, all girls from three countries (France, Portugal and 
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Sweden), with a uniform and striking, progressive encephalopathy. At this point, 
he revisited Rett’s unusual mental retardation syndrome and suggested the 
condition bear his name (Hagberg et al, 1983). In 1991, Bruck and colleagues 
described a set of monozygotic female twins with Rett syndrome (Bruck et al, 
1991). 
The genetic cause of RTT remained evasive until quite recently, largely because 
the inheritance pattern was chiefly sporadic. In 1999, Amir and colleagues (Amir 
et al, 1999) discovered that mutations in the gene encoding Methyl-CpG-binding 
protein 2 (MeCP2) are associated both with rare familial cases of RTT as well as 
with the more common sporadic occurrences of typical RTT. This mutation is 
responsible of 95% of RTT cases (Amir et al, 1999; Van den Veyver & Zoghbi, 
2000; Wan et al, 1999; Xiang et al, 2000). Further, mice lacking MeCP2 display 
Rett-like symptoms, and this phenotype can be reversed with the reintroduction of 
MeCP2 (Guy et al, 2007). 
 
1.2.1 Clinical features of Rett Syndrome 
Girls with RTT born after an apparently quiet pregnancy. They are normal at the 
birth and achieve expected developmental milestones until 6-18 months of age. 
Nevertheless, some studies revealed subtle behavioral abnormalities soon after 
birth. There is a wide variability in the clinical presentation, classic Rett syndrome 
follows a well recognized pattern. Not all symptoms compare at the beginning of 
the disease but can be distinguish four different stages (Figure 2). 
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Figure 2: Onset and Progression of RTT Clinical Phenotypes. 
 
In the development of the disorder, the first indicator of neurological involvement 
is deceleration of head growth, leading to microcephaly by the second year of life. 
This decreased head growth is due to decreased neuronal growth. The acquired 
microcephaly is accompanied by general growth retardation, weight loss, and a 
weak posture brought on by muscle hypotonia.  
Subsequently there is a period of rapid regression and patients lose purposeful use 
of their hands and instead develop stereotypic hand wringing or washing 
movements, and in some cases clapping, flapping, and mouthing of the hands. 
Social withdrawal and loss of language become apparent in addition to irritability 
and self-abusive behavior. Other autistic features also manifest, including 
expressionless face, hypersensitivity to sound, lack of eye-to-eye contact, 
indifference to the surrounding environment, and unresponsiveness to social cues 
(Nomura, 2005). The onset of mental deterioration is accompanied by loss of 
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motor coordination and the development of ataxia and gait apraxia. The earliest 
autonomic perturbation is hyperventilation during wakefulness. Most girls with 
RTT suffer additional breathing anomalies, including breath-holding, aerophagia, 
forced expulsion of air and saliva, and apnea. One of the most arduous features of 
RTT is the occurrence of seizures, which range from easily controlled to 
intractable epilepsy, with the most common types being partial complex and 
tonic-clonic seizures (Jian et al, 2006). The seizures tend to decrease in severity 
after the teenage years and into adulthood, presenting minor problems after the 
age of forty.  
The third stage of the pathology is characterized by an amelioration of the social 
component of the autistic-like behavior occurs sometime between 5 to 10 years of 
age. Behavioral abnormalities during this post regression phase include teeth 
grinding, night laughing or crying, screaming fits, low mood, and anxiety 
episodes elicited by distressful external events (Mount et al, 2001). Patients suffer 
devastating motor deterioration, generalized rigidity, dystonia, and worsening of 
scoliosis. Most girls with RTT lose mobility, and are often wheelchair-bound 
during the teenage years. Sleep problems are common in Rett syndrome (in over 
80% of cases), specifically has been shown disrupted sleep patterns at night and an 
increase in total and daytime sleep (Young et al, 2007). Additional autonomic 
abnormalities include hypotrophic, severe constipation, oropharyngeal 
dysfunction, and cardiac abnormalities, including tachycardia, prolonged 
corrected QT intervals, sinus bradycardia and cold blue feet. Despite their 
excellent appetites, individuals with RTT commonly present eating problems 
(Reilly & Cass, 2001) and not have a correct intake of calories in the diet, 
especially during pre-school and early school years. This can be caused by 
 8 
 
problems in coordinating movements of the mouth and throat, muscle spasms and 
involuntary movements, the expenditure of large amounts of energy when 
breathing and the inability of the intestine to absorb nutrients. They have difficult 
to co-ordinate breathing and swallowing. Patients continue to lose weight and 
many suffer from osteopenia, scoliosis, and rigidity as they age. As patients get 
older they often develop Parkinsonian features (Hagberg, 2005; Roze et al, 2007). 
The condition reaches a plateau and some patients survive up to the sixth or 
seventh decade of life in a severely debilitated physical condition. 
 
1.2.2 The autonomic nervous system 
Certain physical functions including the regulation of heart rate, blood pressure, 
peripheral blood circulation, respiration and digestion are governed by the 
autonomic nervous system. In Rett syndrome there are varying degrees of 
dysfunction in the control of the central autonomic nervous system. 
Abnormal breathing patterns affecting pulmonary and cardiovascular function are 
characteristic of Rett syndrome. They can be divided into three categories: 
forceful breathing, abnormally shallow breathing and apneustic breathing (a series 
of slow deep inspirations). Valsalva breathing (attempting to forcibly exhale while 
the epiglottis is closed) is a common, complication to the breathing abnormalities 
characteristic of Rett syndrome, and affects the autonomic nerve system and brain 
stem functions. The consequences for the individual of Valsalva breathing depend 
on the category of breathing abnormality he or she manifests(Julu et al, 2001). 
Impaired balance of central autonomic control may also result in cold, bluish, 
clammy feet due to peripheral vasomotor disturbances. Hydrotherapy, and 
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physiotherapy to the extremities is often used to regain proper circulation and 
helps to keep their extremities limber (Stearns et al, 2007).  
The motility of the gastrointestinal tract (peristalsis) shifts the food along the tract 
and is controlled and coordinated by the autonomic nervous system. It is common 
that these movements are impaired and that the passage of food through the tract 
is unusually slow, leading to a number of symptoms of varying degrees of 
severity. The girls have problems swallowing and may swallow air resulting in an 
extended, painful stomach, and vomiting. Painful inflammation in the lower 
esophagus (esophagitis) can occur from an early age if the lower esophageal 
sphincter leaks. Severe constipation is very common. 
 
1.2.3 Clinical criteria for typical Rett Syndrome 
In 1994 Hagberg and Skjeldal suggested a model of inclusion and exclusion 
criteria for the diagnosis of RTT that relaxed the international criteria originally 
drawn up in Vienna in September 1984 (Hagberg & Skjeldal, 1994). In 2002 the 
same authors updated the previous diagnostic criteria (Hagberg et al, 2002).  In 
2010 researchers reviewed 2002 diagnostic criteria (Figure 3) to clarify and 
simplify the diagnosis of typical, or classic, RTT. They emphasized that it remains 
a clinical diagnosis, since not all RTT patients have MECP2 mutations and not all 
patients with MeCP2 mutations have Rett syndrome. They limited the necessary 
criteria to the presence of a period of clear developmental regression plus four 
main criteria that are absolutely required for the diagnosis of typical RTT: loss of 
purposeful hand skills, loss of spoken language, gait abnormalities, and 
stereotypic hand movements. After the period of regression, a stage of 
stabilization and potentially even improvement ensues, with some individuals 
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partially regaining skills. This potential for some skill recovery emphasizes the 
importance of the acquisition of a careful history to determine the presence of 
regression. Furthermore they eliminated postnatal deceleration in head growth 
from the necessary criteria because this feature in not found in all individuals with 
typical RTT. However, because it is a clinical feature that can alert a clinician to 
the potential diagnosis and it is a distinctive feature in the disorder, this has been 
included as a preamble to the criteria as a feature that should raise suspicion for 
the diagnosis. In these new criteria, history of regression and all of the necessary 
and exclusion criteria must be met to make the diagnosis of typical RTT, without 
exception (Neul et al, 2010).  
Figure 3: Revised diagnostic criteria 
for Rett Syndrome. 
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1.2.4 Atypical forms of Rett Syndrome  
In addition to the classic form of RTT, five distinct categories of variants have 
been delineated on the bases of clinical criteria (Hagberg et al, 2002; Trevathan & 
Naidu, 1988). These variants show some, but not all diagnostic features of RTT 
and can be milder or more severe. They include:  
i) the preserved speech variant (PSV), is the best characterized, has well-
defined clinical features, and mutations in MECP2 have been found in 
the majority of cases; in this variant girls recover the ability to speak in 
single word or third person phrases and display an improvements of 
purposeful hand movements at stage III of disease progression 
(Zappella et al, 2001);  
ii) the early seizures variant (Hanefeld Variant) , in which the normal 
perinatal period is soon followed by the appearance of seizures 
preceding the regression period (Hanefeld, 1985);  
iii) the “forme fruste” with a milder, incomplete and protracted clinical 
course (Hagberg & Rasmussen, 1986; Hagberg & Witt-Engerstrom, 
1986);  
iv) the congenital variant, where patients show RTT features straight from 
birth (Rolando, 1985);  
v) the late regression variant, which is characterized by normal head 
circumference and gradual loss of acquired speech and fine motor 
skills in late childhood (Gillberg, 1989). 
Furthermore, it has been described a “highly functioning PSV” associated with 
acquisition of more complex language function including the use of first person 
phrases. In this variant, girls acquire a better control of their hands and they are 
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able to draw figures and write simple words (Zappella et al, 2003). The degree of 
mental retardation is milder then in PSV with the I.Q that can be as high as 50. 
Recent works have found mutations in different loci associated with congenital 
and Hanefeld variants, with mutations in FOXG1 found in congenital variant 
cases (Ariani et al, 2008) and mutations in CDKL5 found in early seizure variant 
cases (Bahi-Buisson et al, 2008). 
 
1.2.5 Genetic origin of Rett Syndrome 
Early reports postulated an X-linked dominant mode of inheritance with fateful 
consequences in homozygous males. Using information from rare familial cases, 
exclusion mapping identified the Xq28 candidate region, and subsequent 
screening of candidate genes in RTT patients revealed mutations in MECP2 
(Amir et al, 1999). Mutations in MECP2 are found in more than 95% of classic 
RTT cases, most arise de novo in the paternal germ line and often involve a C to 
T transition at CpG dinucleotides. The spectrum of mutation types includes 
missense, nonsense, and frameshift mutations, with over 300 unique pathogenic 
nucleotide changes described (Christodoulou & Weaving, 2003), as well as 
deletions encompassing whole exons (Archer et al, 2006; Pan et al, 2006; Ravn 
et al, 2005). Eight missense and nonsense mutations account for 70% of all 
mutations, while small C-terminal deletions account for another 10%, and 
complex rearrangements constitute 6%. 
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1.2.6 Effect of XCI 
In each body cell (somatic cell) of the developing baby girl, one of the X 
chromosomes becomes very shortened and condensed so that most of its genes are 
not able to be ‘read’ by the cells.  
This system of inactivation in the body cells known as X-chromosome 
inactivation (XCI) is totally normal in female and is usually random so that 
women’s bodies have a mixture of cells in regard to the inactivated X 
chromosome, although certain genes on the silenced chromosome may still be 
expressed. Some cells will have the X chromosome switched off that came from 
their mother (an inactive maternal X chromosome); other cells will have the 
paternal X chromosome inactivated. The relative proportion of cells with an active 
maternal or paternal X chromosome varies from female to female (even between 
identical twins) because the process is usually random. In rare situations, females 
can show nonrandom or skewed X-inactivation with the preferential inactivation 
of one X-chromosome in most or all of the cells in the body. In these cases, 
females may be protected from expression of X-linked diseases if the X-
chromosome with the abnormal gene is inactivated. XCI only occurs in the 
somatic cells, since both X chromosomes need to be active in the egg cells for 
their normal development.  
Of course this process occurs also in Rett patients and can produce a pattern 
favoring the expression of the X chromosome containing the normal MECP2 
gene, or mutated MECP2 gene. Asymptomatic carriers of RTT can have highly 
skewed inactivation patterns of XCI favoring the normal MECP2 allele. Sisters 
with identical MECP2 mutations can have extremely discordant phenotypes as a 
result of XCI skewing. One sister displayed classic Rett Syndrome while the other 
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was a “highly functioning” preserved speech variant as a result of favourable XCI 
skewing (Scala et al, 2007). XCI patterns may interact with mutation type, so that 
Rett patients with severe early truncating mutation present a milder phenotype 
than would be expected. The process of XCI also occurs in Mecp2-deficient 
female mice models (Young & Zoghbi, 2004). In Mecp2-heterozygotes, XCI 
patterns generally favour the wild-type allele which may in part explain the mild 
phenotype observed (Young & Zoghbi, 2004). 
 
1.2.7 Genotype/Phenotype correlations 
Several studies have addressed the relationship between genotype and phenotype 
directly using scoring systems and statistical methods to compare the severity of 
individual clinical features, with different types of MeCP2 mutations (missense 
mutations vs. nonsense mutations, early truncations vs. late truncating mutations, 
MBD mutations vs. TRD mutations). They evidenced that RTT patients present a 
large phenotypic variability associated with different MeCP2 mutations. Recent 
genotype-phenotype studies showed that severity of RTT phenotype depends on 
the type of the mutation, the genetic background and the X-chromosome 
inactivation (XCI) balance. 
Patients carrying mutations that truncate the protein in the C-terminal domain 
(late truncating mutations) present milder phenotype and are less typical of 
classical Rett Syndrome than those carrying missense or early truncating 
mutations. Jian reported in 2005 that R270X mutation (X representing here a stop 
codon) is associated with elevated mortality; whereas Wan showed that girls 
carrying the same mutations could sometimes present different phenotypes. This 
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observation is consistent with an important role for the XCI balance (Jian et al, 
2005; Wan et al, 1999). 
 
1.2.8 MeCP2 Mutations In Boys 
At the beginning, RTT was considered to be an X-linked dominant disorder girls 
with Rett syndrome would be heterozygous for the defective gene (one normal X-
chromosome and one X-chromosome with the defective gene) and males, who 
only have one X-chromosome, would not survive the gene defect. 
In 1999, Jan and colleagues identified males with Rett syndrome (Jan et al, 1999).  
Interestingly, males with MeCP2 mutations can be classiﬁed in three ways:  
1) MeCP2 mutations normally observed in girls with Rett syndrome result in 
a more severe clinical phenotype in hemizygous males  (Hoffbuhr et al, 
2001; Villard et al, 2000; Wan et al, 1999)    
2) Classical Rett syndrome and nonfatal neurodevelopmental disorder with 
similarities to Rett syndrome have been reported in an XXY Klinefelter’s 
male with a T158M MeCP2 mutation  (Hoffbuhr et al, 2001)  and a boy 
showing somatic mosaicism for 2 bp deletion in the MeCP2 gene 
(Clayton-Smith et al, 2000)  
3) A subset of novel MeCP2 mutations (A140V, Q406X, G428S, E137G, 
R167W, P399L, R453Q), not identiﬁed in girls with Rett syndrome, has 
been found in several familial cases and ﬁve sporadic cases of nonspeciﬁc 
X-linked mental retardation in boys (Couvert et al, 2001; Imessaoudene et 
al, 2001; Meloni et al, 2000; Orrico et al, 2000). 
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1.3 MECP2 GENE: Structure and Function 
The MECP2 gene is located in Xq28 between the IRAK and RCP genes. The 
MeCP2 protein is a chromatin-associated protein identified and purified for the 
first time in 1992 by Dr Adrian Bird on basis of its capacity to bind methylated 
DNA (Lewis et al, 1992) (Figure 4). MeCP2 is the “founding member” of the 
methylated DNA binding protein (MBP) family. In order it is also the first MBP 
found to interact with HDAC-containing complexes, linking two epigenetic 
repression mechanism: DNA methylation and histone deacetylation (Nan et al, 
1998). It is required for maturation of neurons and is developmentally regulated 
(Swanberg et al, 2009). 
 
 
Figure 4: Transcriptional repression by MeCP2. 
 
The protein is present in all vertebrates, including the sea lamprey, a primitive 
jawless vertebrate, but no MeCP2 ortholog has been detected in invertebrate 
animals or in plants. Among mammals the MeCP2 protein is highly conserved. 
Sequences from human and mouse, for example, which diverged from a 
common ancestor ∼75 million years ago, are 95% identical at the amino acid 
level. Divergences between mammalian MeCP2 and amphibian or ﬁsh MeCP2 
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are more extensive (33% amino acid identity between human and zebraﬁsh), but 
conserved domains are present. 
MECP2 consists of four exons that code for two different isoforms of the protein 
produced by alternative splicing of a short segment at the extreme N-terminus of 
the protein (Figure 5).  
 
Figure 5: Alternative splicing forms of the MECP2: MECP2-e1 and 
MECP2-e2. 
 
The MeCP2-e2 isoform was the first identified variant of MeCP2 and therefore 
the best characterized, but the MeCP2-e1 isoform is more abundant in the brain 
of both mouse and human (Mnatzakanian et al, 2004). 
The MECP2-e1 isoform contains 24 amino acids encoded by exon 1 and lacks 
the 9 amino acids encoded by exon 2, whereas the start site for the MECP2-e2 
isoform is in exon 2 (Dragich et al, 2007; Kriaucionis & Bird, 2004; 
Mnatzakanian et al, 2004). The two splice variants differ in translation efficiency 
and are expressed at different relative amounts in different tissues. MECP2-e1 is 
more abundant in the brain, thymus and lung and during neuronal differentiation. 
However, recent studies show that both of these isoforms co-localize to 
heterochromatic regions in murine fibroblastic cells (Kumar et al, 2008). These 
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two MeCP2 isoforms present differences in structure and distribution, but not in 
function. MeCP2 protein levels are low during embryogenesis and increase 
progressively during the postnatal period of neuronal maturation (Balmer et al, 
2003; Cohen et al, 2003; Kishi & Macklis, 2004; Mullaney et al, 2004; 
Shahbazian et al, 2002b). Both MeCP2 isoforms are nuclear and co-localize with 
methylated heterochromatic foci in mouse cells. A recent report suggests that 
MeCP2 translocates to the nucleus upon neuronal differentiation (Miyake & 
Nagai, 2007). 
Since MeCP2 is expressed in mature neurons and its levels increase during 
postnatal development, MeCP2 may play a role in modulating the activity or 
plasticity of mature neurons. Consistent with this, MeCP2 mutations do not seem 
to affect the proliferation or differentiation of neuronal precursors. Although the 
mechanisms that regulate the complex MeCP2 expression patterns are unknown. 
Recent studies identified the core promoter and several cis-regulatory elements 
that drive MeCP2 expression (Liu & Francke, 2006). These regulatory 
sequences may dictate the spatial and temporal patterns of MeCP2 expression. 
MeCP2 is composed of three domains: the methyl-binding domain (MBD), the 
transcriptional repression domain (TRD), and a C-terminal domain, in addition 
to two nuclear localization signals (NLS) (Figure 6). 
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MeCP2 
 
Figure 6: MeCP2 function domains. MBD methyl-binding domain; TRD 
transcriptional repression domain; C-ter C-terminal domain and NLS 
nuclear localization signals. 
 
The MBD, an 85 amino acids domain is located on exons 3 and 4 (from amino 
acid 78 to 162 in MeCP2), and specifically binds to methylated CpG 
dinucleotides, with preference for CpG sequences with adjacent A/T-rich motifs 
(Klose et al, 2005). MBD also binds to unmethylated four-way DNA junctions 
with a similar affinity (Galvao & Thomas, 2005), implicating a role for the 
MeCP2 MBD in higher-order chromatin interactions. The TRD is a 104 amino 
acids domain, situated on exon 4 (from amino acid 207 to 310), important in 
generating a physical association with the transcriptional corepressor Sin3a, 
which recruits the histone deacetylases HDAC1 and HDAC2. These histone 
deacetylases remove acetyl groups from histones, resulting in a compact 
chromatin structure that represses local gene expression (Jones et al, 1998; Nan 
et al, 1997). The C-terminal region of MeCP2 is not yet well characterized, it is 
clearly essential for protein function as evidenced by the numerous RTT-causing 
mutations that involve deletion of this domain, and the fact that a mouse model 
lacking the MeCP2 C-terminus reproduces many RTT phenotypes (Shahbazian 
et al, 2002a). The C-terminal region has been described as containing a WW 
binding domain important for MeCP2 interactions with splicing factors 
(Buschdorf & Stratling, 2004). WW domains are characterized by the presence 
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of 2 tryptophan residues (W) that are separated by 20-22 amino acids and that 
recognize proline residues of interacting ligands. 
The function of MeCP2 as a transcriptional repressor was first suggested on the 
basis of in vitro experiments in which MeCP2 specifically inhibited transcription 
from methylated promoters (Nan et al, 2007). When MeCP2 binds to methylated 
CpG dinucleotides of target genes via its MBD, its TRD recruits the corepressor 
Sin3A and HDAC 1 and HDAC 2 (Jones et al, 1998; Nan et al, 1998)( Figure 7).  
 
 
Figure 7: MeCP2 as a transcriptional repressor. MeCP2 binds to 
methylated CpG upstream of the transcriptional start site of a MeCP2 
target gene.  
 
The transcriptional repressor activity of MeCP2 involves compaction of 
chromatin by promoting nucleosome clustering, either through recruitment of 
HDAC and histone deacetylation or through direct interaction between its C-
terminal domain and chromatin (Nikitina et al, 2007). Additional MeCP2-
interacting proteins include the catalytic component of the SWI/SNF chromatin- 
remodeling complex Brahma (at least in NIH 3T3 cells), the DNA 
methyltransferase DNMT1, the histone methyltransferase Suv39H1, the 
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transcription factors TFIIB and PU.1, the corepressors c-Ski and N-CoR, LANA, 
and the SWI2/SNF2 DNA helicase/ATPase responsible for a-thalassemia/ 
mental retardation syndrome X-linked (ATRX) (Harikrishnan et al, 2005; 
Kaludov & Wolffe, 2000; Kimura & Shiota, 2003; Nan et al, 2007).  
In 2005, has been demonstrated that MeCP2 in addition to its role as a global 
repressor, acts as a splicing regulator (Young et al, 2005). The authors identified 
the RNA-binding protein Y box-binding protein 1 (YB1), a principal component 
of messenger ribonucleoprotein particles that controls multiple step of mRNA 
processing, as a MeCP2 binding partner. The functional significance of this 
interaction was investigated by determining whether the MeCP2-YB1 complex 
affects mRNA processing and splice-site selection. It has been shown that in 
MeCP2-deficient neurons, the splicing is altered, and aberrantly spliced 
transcripts can be produced (Young et al, 2005). 
Given that MeCP2 interacts with other proteins, chromatin, DNA, and RNA, it is 
clearly a multifunctional protein, with roles in chromatin remodeling and RNA 
splicing. 
In contrast to the data showing that MeCP2 is only a transcription inhibitor, in 
2008, Chahrour and colleagues carried out a study to examine gene expression 
patterns in the hypothalamus of MeCP2-null and transgenic mice. Surprisingly, 
authors found that the majority of genes displaying altered expression were up-
regulated rather than down-regulated by MeCP2 (Figure 8), and that, in these 
neurons, MeCP2 protein was directly associate with the transcriptional activator 
CREB1 (Chahrour et al, 2008). An increased level of CREB1 induces miR132 
microRNA and represses MeCP2 translation suggesting a negative regulatory 
loop between MeCP2 and CREB1 (Klein et al, 2007). These results confirm 
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another study, in which, by using ChIP-on-chip analysis in SH-SY5Y cells, 
MeCP2 has been found associated more frequently with promoters that are also 
associated with RNA polymerase II (Yasui et al, 2007). All these data suggest 
that MeCP2 would be a "transcriptional modulator" rather than a repressor. 
 
 
Figure 8: MeCP2 as a transcriptional activator. MeCP2 recruits a 
transcriptional coactivator to cause the transcriptional upregulation of a 
target gene. 
 
 
1.3.1 Tissue expression of MeCP2 
Several studies, carried out in rodents (Cassel et al, 2004; Mullaney et al, 2004; 
Shahbazian et al, 2002b) monkeys (Akbarian et al, 2001) and human 
(Shahbazian et al, 2002b), were aimed to analyze the expression profile of 
MeCP2. From these studies appears that MeCP2 is expressed in many tissues. 
Analysis on mice tissue samples revealed that the MeCP2 protein is not 
abundant in liver, stomach and small intestine, moderately expressed in kidney 
and heart and highly abundant in brain, lung and spleen (Shahbazian et al, 
2002b). Within the cerebral tissue, MeCP2 is not abundant in astrocytes 
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(Maezawa et al, 2009) and immature neurons, but is preferentially expressed in 
mature neurons. The timing of its appearance correlated with the ontogeny of 
central nervous system. MeCP2 expression followed a similar time course in 
both mouse and human, with its early expression in the spinal cord and 
brainstem, and late expression in the hippocampus and cerebral cortex (Figure 
9). 
  
 
Figure 9: Schematic representation of the spatial and temporal distribution 
of MeCP2 during human (A) and mouse (B) development. Wg, weeks of 
gestation. 
 
Direct quantiﬁcation in adult mouse brain has estimated ∼16 million molecules 
of MeCP2 per nucleus in neurons with almost an order of magnitude less in glial 
cells and 30-fold less in liver cells (Skene et al, 2010). The neuronal MeCP2 
level is relatively low at birth but, in the mouse, increases greatly during the ﬁrst 
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3 weeks of life before reaching a plateau (Kishi & Macklis, 2004; Skene et al, 
2010). Because neurogenesis is largely complete before birth, the increase is due 
to up-regulation of MeCP2 expression within a constant number of neurons. 
These neurons are, however, developmentally active, undergoing synaptogenesis 
at this time. MeCP2 expression varies between neuronal populations from 
different regions and different structures within the central nervous system 
(LaSalle et al, 2001). MeCP2 expression is regulated in a developmental stage 
and cell type specific manner. Few things are known about molecular 
mechanisms implicated in this regulation. It was shown that the MeCP2 gene 
contains multiple transcription starting sites embedded in a region that is GC 
rich and contains CpG islands. In this study has been showed that the mouse 
MeCP2 promoter does not contain any canonical boxes like TATA or CAAT. 
They also identified a promoter region (-677/+56) that is responsible for the 
expression of MeCP2 in neuronal cells. In this region, there is a positive 
regulatory element of 19 bp (-64 to +46) that controls the major activity of the 
promoter region (Adachi et al, 2005). 
Anatomically, MeCP2 deficiency causes reduced brain size. This may be due to 
size decreases in major brain regions such as the frontal and temporal lobes, 
caudate nucleus, thalamus, midbrain, and cerebellum, all of which have been 
documented in RTT patients (Armstrong et al, 2001; Reiss et al, 1993; Saywell et 
al, 2006; Subramaniam et al, 1997). At the cellular level, the neuronal soma is 
smaller in the absence of MeCP2, and cells are more densely packed, with 
decreased dendritic complexity (Armstrong, 2005; Chen et al, 2001; Kaufmann & 
Moser, 2000; Taneja et al, 2009). Importantly, degeneration and atrophy are not 
observed, establishing the notion that RTT is a postnatal developmental disorder, 
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rather than a neurodegenerative disorder (Armstrong, 2005; Jellinger et al, 1988; 
Jellinger & Seitelberger, 1986). 
More specific abnormalities have been observed at the synapses. Postmortem 
brain samples from RTT patients or MeCP2-deficient mice present postsynaptic 
morphological defects such as reduced dendritic branching, reduced dendritic 
spine density, and defects in spine morphology (Armstrong et al, 1995; Armstrong 
et al, 2001; Belichenko et al, 1994; Chapleau et al, 2009; Fukuda et al, 2005; 
Kishi & Macklis, 2004; Schule et al, 2008; Smrt et al, 2007) (Figure 10). 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic representation of pyramidal neurons from control and 
Rett brains. 
 
Presynaptically, lack of MeCP2 is associated with an abnormal number of axons 
(Belichenko et al, 2009a) and a defect in axonal targeting (Belichenko et al, 
2009b; Matarazzo et al, 2004; Palmer et al, 2008). Overall, the structural defects 
described at the synapse would suggest that loss of MeCP2 triggers alterations in 
the functioning of the synapses and, consequently, of the neuronal networks. 
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Analysis of neurotransmission associated with loss of MeCP2 provides further 
evidence for synapse dysfunction. Postmortem analysis in RTT brains showed 
altered levels of neurotransmitters such as glutamate and biogenic amines as well 
as changes in the abundance of some neurotransmitter receptors. In mice, reduced 
levels of serotonin (5- hydroxytryptamine), adrenaline, and dopamine have been 
found in the MeCP2-null brain (Ide et al, 2005; Isoda et al, 2010; Samaco et al, 
2009; Santos et al, 2010). Analysis of spontaneous miniature excitatory and 
inhibitory postsynaptic currents indicated a shift in the excitatory/inhibitory (E/I) 
balance, with increased excitatory and decreased inhibitory neurotransmission in 
the hippocampus and cortex (Chao et al, 2007; Dani et al, 2005; Nelson et al, 
2006; Wood & Shepherd, 2010; Zhang & Minassian, 2008). This is supported by 
data showing pre- and postsynaptic defects of GABA and therefore inhibitory, 
neurotransmission in the brainstem (Medrihan et al, 2008). Consistent with the 
idea of disturbance of the E/I balance, long-term potentiation (LTP) is also altered 
in the hippocampus of symptomatic MeCP2-deficient mice (Asaka et al, 2006; 
Guy et al, 2007; Weng et al, 2011). These data, added to the morphological 
studies, imply that loss of MeCP2 causes malfunction of numerous synapses 
throughout the brain, which creates less efficient neuronal networks and gives rise 
to RTT-like phenotypes. 
 
1.3.2 MeCP2 genes target 
The identification of MeCP2 genes target has always been one of the main 
objectives of many researchers. This will allow you to better understand the 
correlation between the presence of MeCP2 mutations and clinical manifestations 
of RTT and to think about how to make up for excess or deficiency of certain 
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proteins in these patients. Many studies with microarrays, with which it is possible 
to simultaneously evaluate the expression of a large number of genes, have 
contributed to uniquely identify a few target genes (Chahrour & Zoghbi, 2007) 
(Figure 11). 
 
 
Figure 11: MeCP2 Target Genes. 
 
In 2003, BDNF has been identified as the first MeCP2 target in mammals (Chen 
et al, 2003; Martinowich et al, 2003). BDNF is a neurotrophin essential for 
survival, growth, differentiation and maintenance of neurons during development 
(Ghosh et al, 1994). In the brain, it is active in the hippocampus, cortex, and basal 
forebrain-areas vital to learning, memory, and higher thinking (Yamada & 
Nabeshima, 2003). BDNF itself is important for long-term memory (Bekinschtein 
et al, 2008). 
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The role of BDNF in the pathogenesis of RTT is still unknown and it is unknown 
how the absence of MeCP2 results in a malfunction of BDNF and if this 
contributes to the neurological patients phenotype. In cultured neonatal cortical 
neurons, basal BDNF transcription is repressed by MeCP2 in the absence of 
neuronal activity, but activity-dependent upregulation of BDNF is unaffected by 
MeCP2 deletion (Chen et al, 2003). Chang and colleagues have shown that BDNF 
protein level in the whole-brain lysate in MeCP2 mutant mice was decreased to 
about 70% of the wild-type level (Chang et al, 2006). To further investigate the in 
vivo role of BDNF in RTT, BDNF expression has been manipulated in the 
postnatal brains of MeCP2-deﬁcient mice and discovered that deleting BDNF 
from the MeCP2 mutant brain resulted in an earlier onset/accelerated disease 
progression, whereas overexpressing BDNF in the MeCP2 mutant brain led to 
later onset/slower disease progression. So they demonstrated in vivo a functional 
interaction between MeCP2 and BDNF and suggested that RTT may be a human 
disease that is partially mediated through BDNF. 
Recently, Zhou and colleagues demonstrated that the phosphorylation of a 
specific amino acid residue S421 of MeCP2 controls the ability of the protein to 
regulate dendritic patterning, spine morphogenesis and the activity dependent 
induction of  Bdnf transcription (Zhou et al, 2006). These findings suggest that, by 
triggering MeCP2 phosphorylation, neuronal activity regulates a program of gene 
expression that mediates neuronal connettivity in the nervous system.  
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1.4 Rett Mouse Models  
With the discovery of the gene that causes the Rett Syndrome, several MeCP2 
deficient mice models of RTT have been developed. Their creation has allowed 
examine the relationship between molecular and anatomical changes of the 
disease and associated behavioral abnormalities. These models also represent an 
extraordinary tool to test therapeutic interventions that may lead to improved an 
eventual cure for this devastating disease (Stearns et al, 2007). 
Several mouse models currently exist (Figure 12).  
 
Figure 12: Lifespan and progression of symptoms of selected mouse models. 
 
Three constitutive knockout models result in the loss of functional MeCP2 protein 
and were created using the technique of Cre-loxP recombination (Nagy, 2000).  
In Dr Bird’s laboratory, mice with deletions of exons 3 and 4 of MeCP2 
(Mecp2
tm1-1Bird
 ,which comprises nearly the entire protein) were created (Guy et al, 
2001). Dr Jaenisch’s lab produced a MeCP2-deficient mice model in which was 
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deleted only exon 3 (Mecp2
1lox
), which contains a large part of the MBD domain 
(Chen et al, 2001). Both models produce MeCP2-null mice and MeCP2-
heterozygotes, and result in similar phenotypes. MeCP2-null male mice are 
apparently healthy at birth until 3 weeks of age. After this period, mice begin to 
show neurological symptoms like those observed in RTT patients: stiff and 
uncoordinated gait, hind limb clasping, and irregular breathing. Uneven wearing 
of the teeth and misalignment of the jaws are also observed. Testes of MeCP2-null 
males were always internal. Symptoms progression leads to weight loss and early 
death around 54 days. Brain architecture in null mice is grossly normal, although 
a slight decrease in the size and weight can be noticed in comparison with wild-
type littermates. This is due to neurons compaction in hippocampus, cerebral 
cortex and cerebellum. Total brain weight was reduced 9 to 13% compared to 
wild-type controls. Cortical brain volume was decreased between 7 to 11% and 
hippocampal volume was decreased 8% (Belichenko et al, 2008). By comparison, 
an autopsy study of  Rett girls found brain weight to be reduced 12 to 34% 
relative to age-matched controls (Jellinger et al, 1988). MeCP2
+/−
 females mice 
are viable, fertile and grow normally until adulthood. At 3 months, they start 
showing hind limb clasping and by 6 months they show RTT phenotypes such as 
breathing irregularity and inertia. These results show that MeCP2-null mice can 
be a good model to study RTT because of delayed onset of neurological 
symptoms affecting posture, gait, breathing and spontaneous movements. In 2006, 
Dr Patrick Tam generated mice with a targeted deletion of the methyl binding 
domain (MBD) resulting in complete loss of MeCP2 protein (Mecp2
tm1Tam
, (Pelka 
et al, 2006). MeCP2
tm1Tam
 phenotype is comparable with that of the Jaenisch and 
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Bird’s mice phenotype. In addition, at 8 to 10 weeks after birth, they display 
reduced level of anxiety, locomotors activity and cerebellar learning (Figure 13).  
 
Figure 13: Rett mice phenotype. 
 
In the fourth model, the MeCP2 protein is truncated after codon 308 (Mecp2
308
), 
retaining several key functional domains (Shahbazian et al, 2002a). In these mice 
the phenotype is milder than those seen previously. MeCP2
308/y 
are normal until 6 
weeks and then they develop symptoms like tremors, kyphosis, learning and 
memory deficits, social behavior abnormalities, etc. Heterozygote females 
MeCP2
308/+ 
have impaired motor features starting at 35-39 weeks after birth. As in 
the case of human female patients, these mice show phenotypic variability due to 
the XCI. MeCP2-deficient models are reminiscent of RTT in that autonomic 
misregulation occurs (tremor, breathing irregularities, weight abnormalities), 
smaller brain and neuronal size is observed, posture and motor coordination are 
abnormal, and seizures may be present (Chen et al, 2001; Guy et al, 2001; 
Shahbazian et al, 2002a). Additionally, Rett mice show a similar developmental 
progression to Rett girls, appearing normal at birth, achieving motor and 
developmental milestones early on, and showing a delayed onset of symptoms. 
Mecp2-deficient mice show similar neurochemistry to Rett girls; cholinergic 
markers are low in the brains of Rett girls and Rett mice show phenotypic 
improvement in response to dietary cholinergic supplementation (Nag & Berger-
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Sweeney, 2007; Wenk, 1997). Also, studies on Rett mice models are consistent 
with the view that RTT is mainly a synaptic disorder. Synaptic plasticity is 
impaired in Rett mice models, dendritic spines, the principal site of excitatory 
neurotransmission, are greatly reduced, and there appears to be an overall 
imbalance between excitation and inhibition (Armstrong, 2005; Dani et al, 2005). 
Recently neuron-specific or regional MeCP2 deletion studies reproduce some 
aspects of Rett syndrome. Has been demonstrated that loss of MeCP2 from 
dopaminergic neurons causes motor incoordination whereas loss from 
serotoninergic neurons leads to increased aggression (Samaco et al, 2009); 
furthermore the loss of MeCP2 from amygdale impairs amygdale-dependent 
learning and memory (Adachi et al, 2009) and MeCP2 deletion in hypothalamic 
Sim1-expressing neurons leads to alterations in feeding behavior, aggression and 
stress response (Fyffe et al, 2008). Postnatal loss of MeCP2 from forebrain 
excitatory neurons produces motor incoordination, increased anxiety-like 
behaviours and impaired fear conditioning and social behavior (Gemelli et al, 
2006). In the last year Lioy and colleagues showed that in globally MeCP2-
deficient mice, reexpression of MeCP2 preferentially in astrocytes significantly 
improved locomotion and anxiety levels, restored respiratory abnormalities to a 
normal pattern, and greatly prolonged life span compared to globally null mice. 
Furthermore, restoration of MeCP2 in the mutant astrocytes exerted a non-cell-
autonomous positive effect on mutant neurons in vivo, restoring normal dendritic 
morphology and increasing levels of the excitatory glutamate transporter 
VGLUT1. Finally, they concluded their study showed that glia, like neurons, are 
integral components of the neuropathology of Rett syndrome, and supported the 
targeting of glia as a strategy for improving the associated symptoms. 
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1.5 Oxidative stress in Rett Syndrome 
The antioxidant enzymatic system is one of the most important free radical 
detoxification mechanisms. The enzymes act in equilibrium, and any unbalance of 
this system may provoke oxygen-derived free radical generation. Free radicals are 
extremely reactive molecules that can disrupt lipid cell membranes, destroy cell 
enzyme functions, alter DNA, and lead to cell death (Shadid et al, 1998; Thomas 
& Aust, 1985). Free radicals appear to play a role in the pathogenesis of Rett 
syndrome (Sofic et al, 1987). 
There is an increasing amount of experimental evidence that oxidative stress 
caused by oxygen free radicals is involved in the neuropathology of several 
neurodevelopmental and neurodegenerative disorders, as well as in stroke and 
seizures (Coyle & Puttfarcken, 1993).  
A growing body of evidence supported the association between oxidative stress 
and stereotyped movements in different animal models and in patients affected by 
neurological disorders such as obsessive compulsive disorders or autism 
(Ghanizadeh, 2011; Ghanizadeh, 2012; Guldenpfennig et al, 2011). 
Elevated cerebrospinal fluid glutamate has been found in Rett syndrome 
(Hamberger et al, 1992). The neurotransmitter glutamate can provoke oxidative 
stress in cells (Coyle & Puttfarcken, 1993). Moreover, a postmortem study of a 
case with RTT showed a severe reduction of ascorbic acid and reduced 
glutathione levels in most brain regions (Sofic et al, 1987). Ascorbic acid and 
glutathione play an important role in the antioxidant control system, preventing 
excessive accumulation of free radicals in living tissue. The authors suggested that 
the impairment of these defense mechanisms could indicate a process of 
progressive neurological illness with mental retardation and delayed motor 
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development. High levels of malondialdehyde reflect peroxidative damage of bio-
membranes that might contribute to progressive dementia, impaired motor 
function, behavioral changes, and seizures (Buss & Winterbourn, 2002; Dalle-
Donne et al, 2003). Any relationship was found between malondialdehyde levels 
and the clinical stages of pathology in a large number of patients. However, 
malondialdehyde levels were significantly lower in patients with moderate 
phenotype compared with patients with severe clinical phenotype. These results 
indicate that free radicals generated from oxidation reactions might contribute to 
the pathogenesis of Rett syndrome. 
Formichi et al. (Formichi et al, 1998) found low serum vitamin E levels in nine of 
28 patients with RTT. These results indicated that the oxidative free radical 
metabolism might be impaired in some patients with Rett syndrome.  
Interestingly, Brain-derived neurotrophic factor (BDNF), a MeCP2 gene target, 
that is down-regulated both at the RNA and protein levels in MeCP2-null mice, 
can protect neurons against oxidative damage resulting from different 
neuropathologic insults(Mattson, 2002). Is reasonable to assume that oxidative 
stress detected in Rett syndrome is at least partly due to decreased levels of 
BDNF. Likewise, the cAMP-responsive-element binding protein (CREB) is 
recently reported as another molecular target of MeCP2 (Chahrour et al, 2008), 
can produce a lipid peroxidation-induced differential regulation thought to play a 
role in neurodegenerative disease such as Alzheimer disease (Pugazhenthi et al, 
2006). 
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1.6 Vascular Function 
While the neurological phenotype of the Rett syndrome has been well-
characterized in animal models and in humans, few studies focused on alterations 
in the cardiovascular system of MeCP2 deficient mice (Bissonnette et al, 2007; 
McCauley et al, 2011), but nobody specifically investigated the vascular functions 
in this pathology.  
An important role in the vascular functions is played by the endothelium: a thin 
layer of cells that serves not merely as a passive barrier between flowing blood 
and the vascular wall but uses this strategic location to maintain vascular 
homeostasis. The healthy endothelium is able to respond to physical and chemical 
signals by production of a wide range of factors that regulate vascular tone, 
cellular adhesion, thromboresistance, smooth muscle cell proliferation, and vessel 
wall inflammation. The importance of the endothelium was first recognized by its 
effect on vascular tone. Pioneering experiments by Furchgott and Zawadzki1 
showed that the presence of intact endothelium was essential for acetylcholine 
(ACh) to induce dilation of isolated arteries. In contrast, if the endothelium was 
removed, the arteries constricted in response to ACh. Subsequent studies revealed 
that ACh stimulated the release of a potent vasodilating substance by the 
endothelium, identified as nitric oxide (NO) (Furchgott, 1996; Ignarro et al, 
1987). NO is probably the most important and the best characterized mediator, 
and its intrinsic vasodilator function is commonly used as a surrogate index of 
endothelial function. It is generated from L-arginine by the action of endothelial 
NO synthase (eNOS) in the presence of cofactors such as tetrahydrobiopterin 
(Forstermann & Munzel, 2006). NO produces vasodilation primarily by activating 
guanylyl cyclase in vascular smooth muscle cells, which increases intracellular 
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concentrations of cyclic-3’,5’-guanosine monophosphate (cGMP) (Arnold et al, 
1977). cGMP in turn acts as a second messenger, activating cGMP-dependent 
protein kinase, which decreases cytosolic calcium concentration and modulates 
ion channel function leading to relaxation of vascular smooth muscle cells 
(Lincoln & Cornwell, 1993). NO inhibits platelet aggregation and adhesion by a 
guanylyl-cyclase mechanism (Radomski et al, 1990). Endothelium-devived NO is 
an inhibitor of leucocyte adhesion at the vessel wall (Kubes et al, 1991), and has 
anti-mitogenic effects on vascular smooth muscle cells (Garg & Hassid, 1989) 
(Figure 14). Thus, it is clear how in normal vascular physiology, NO plays a key 
role to maintain the vascular wall in a quiescent state by inhibition of 
inflammation, cellular proliferation, and thrombosis. Normal NO release opposes 
the vasoconstrictor responses to clinically relevant stimuli including 
catecholamines and serotonin (Golino et al, 1991; Vita et al, 1992). NOS 
inhibition is associated with increased systemic blood pressure, decreased blood 
flow responses to exercise and local ischemia (Gilligan et al, 1994; Meredith et al, 
1996), and shortened bleeding time.  
 
Figure 14: Nitric oxide in the regulation of vasodilation. 
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Failure of endothelium to elicit NO-mediated vasodilation is caused by reduced 
bioavailability of endothelium-derived NO due to either decreased formation or 
accelerated degradation. A large body of evidence shows that accelerated 
degradation of NO by reactive oxidant species (ROS) accounts for a large 
proportion of reduced NO bioavailability and endothelial dysfunction in vascular 
disease states. Both excess generation of ROS including superoxide anion and 
oxidized LDL cholesterol and decreased antioxidant defense mechanisms 
contribute to enhanced degradation of NO (Kojda & Harrison, 1999).  
Superoxide anion can directly inactivate NO by reacting very rapidly to form 
peroxinitrite, which is vasoinactive and a powerful, damaging oxidant more stable 
than either superoxide or NO (Gryglewski et al, 1986; Rubanyi & Vanhoutte, 
1986). In human blood vessels, increased superoxide production is also associated 
with impaired NO-mediated vasorelaxation (Landmesser et al, 2000).  
Another consequence of increased production of ROS in the vasculature is lipid 
peroxidation. Oxidized LDL is cytotoxic to endothelial cells. It can react with NO 
directly and eliminate its biological activity or interfere with signal transduction 
and receptor-dependent stimulation of NOS activity and with activation of 
guanylyl cyclase. 
Given the relationship between increased oxidative stress in the vasculature and 
impaired endothelial vasodilator function, researchers considered the possibility 
that augmenting antioxidant defenses would have a beneficial effect. For example, 
Vitamin E supplementation improves the bioactivity of endothelium-derived NO 
in hypercholesterolemia and in diabetes mellitus (Andersson et al, 1994; Keegan 
et al, 1995). Vitamin C improves endothelium-dependent vasodilation by 
restoring nitric oxide activity in essential hypertension (Taddei et al, 1998).  
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Reduced NO formation may also contribute to endothelial dysfunction. Although 
the NO-producing enzyme eNOS is constitutively expressed by endothelial cells, 
its expression is subject to modulation by shear stress, atherogenic lipoproteins, 
and cytochines. Altered eNOS expression may affect NO synthesis. Several 
pathways can regulate eNOS expression and function.  
In vitro data demonstrate a selective and differential presence of MeCP2 at 
promoter level of eNOS endothelial cells and vascular smooth muscle cells (Chan 
et al, 2004; Fish et al, 2005). These findings are in line with data in humans, 
reporting elevated plasma levels of oxidative stress in MeCP2-RTT patients, 
together with a decreased superoxide dismutase activity, and increased markers of 
lipid peroxidation (De Felice et al, 2009; Sierra et al, 2001). 
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1.7 Curcumin 
Natural plant products have been used throughout human history for various 
purposes and its role in human healthcare cannot be underestimated. In 
developing countries, approximate 80% of individuals depend primarily on 
natural products to meet their healthcare needs. 
Curcumin (C21H20O6) is a natural product in use for thousands of years. It is an 
active constituent of Curcuma longa Linn (Zingiberacee) a perennial herb that 
grows in South and Southeast Asia. The main component turmeric is from the 
rhizome, or root of the plant. The 2% of curcumin is extracted in 95% ethanol for 
24 hours, then filter and dry. Curcumin is classified as a polyphenol compound 
that gives turmeric its bright yellow color. Figure 15 shows the physical look of 
Curcuma longa and curcumin extract.  
 
 
Figure 15: The physical look of Curcuma longa: plant and powder. 
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In 1910 Milobedzka and colleagues described its chemical structure and shown to 
be diferuloylmethane. The major curcuminoids found in turmeric (about 3-5%) 
include demethoxycurcumin (curcumin II) and bisdemethoxycurcumin (curcumin 
III) and recently was identified cyclocurcumin (Figure 16). 
 
 
Figure 16: Chemical structure of the major curcuminoids. 
 
Turmeric is used as a dietary spice, coloring agent in foods and textiles, and as 
treatment for a wide variety of aliments. Curcumin holds a high place in ayurvedic 
medicine as a “cleanser of the body,” (Ammon & Wahl, 1991) and today, science 
has documented several diseased conditions that can be healed by the active 
ingredients of turmeric (Mishra & Palanivelu, 2008; Nair et al, 2010) . Several 
studies evidenced that curcumin possesses anti-oxidant, anti-inflammatory, 
neuroprotective, anti-cancer, antiviral, antibacterial and antifungal properties and 
has been found that this phytochemical potentially prevents and treats 
cardiovascular, pulmonary, metabolic, neurodegenerative, autoimmune and other 
chronic illness like neoplastic diseases (Aggarwal & Harikumar, 2009; Sandur et 
al, 2007). 
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1.7.1 Metabolism and Bioavailability 
Clinical trials have shown that curcumin amount required for disease management 
i.e.  minimum of 8 g/day and it is safe even at high doses (12 g/day) in humans 
but exhibit poor bioavailability (Lao et al, 2006) due to insolubility in water, poor 
absorption and rapid metabolism.  
It was shown that oral consumption of 1 g/kg curcumin in rats resulted in 
approximately 75% being excreted in the feces and only traces appeared in the 
urine (Wahlstrom & Blennow, 1978), whereas intra-peritoneal administration 
accounted for similar levels of fecal excretion of curcumin, with only 11% found 
in bile (Holder et al, 1978) suggesting poor absorption of curcumin from the 
intestine. Numerous studies revealed that curcumin is bio-transformed to 
dihydrocurcumin and tetrahydrocurcumin and subsequently, these products are 
converted to monoglucuronide conjugates (Pan et al, 1999). These metabolites are 
detected in plasma or serum following oral consumption. It was reported that the 
main biliary metabolites of curcumin are glucuronide conjugates of 
tetrahydrocurcumin (THC) and hexahydrocurcumin (Holder et al, 1978). 
Curcumin metabolites may not have the same biological activity as the parent 
compound. Recently, a clinical trial conducted in the UK found that plasma 
concentrations of curcumin, curcumin sulfate, and curcumin glucuronide were in 
the range of 10 nanomoles/liter (0.01 micromole/liter) one hour after a 3.6 g oral 
dose of curcumin (Sharma et al, 2004). Curcumin and its metabolites could not be 
detected in plasma at doses lower than 3.6 g/day. Surprisingly, analysis of urine 
suggested the presence of curcumin and its conjugates in all samples from patients 
consuming this dose.  
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There are evidences that orally administered curcumin accumulates in 
gastrointestinal tissues. For instance, when colorectal cancer patients took 3.6 
g/day of curcumin orally for seven days prior to surgery, curcumin was detected 
in malignant and normal colorectal tissue and only trace were found in the 
peripheral circulation (Garcea et al, 2005). In contrast, curcumin was not detected 
in the liver tissue of patients with liver metastases of colorectal cancer after the 
same oral dose of curcumin and also in this case only trace were found in 
peripheral circulation (Garcea et al, 2004), suggesting that oral curcumin 
administration may not effectively deliver curcumin to tissues outside the 
gastrointestinal tract. To improve the bioavailability of curcumin, numerous 
approaches have been undertaken. These approaches involve the use of adjuvant 
like piperine that interferes with glucuronidation, the use of liposomal, 
nanoparticles, phospholipid complexes and structural analogues of curcumin. 
 
1.7.2 Biological Activity 
Curcumin exhibits strong antioxidant activity, comparable to vitamins C and E 
and appears to have a significant potential in the treatment of multiple diseases 
that are the result of oxidative stress. In fact, this yellow pigment effectively 
scavenges reactive oxygen species including superoxide anion radicals, hydroxyl 
radicals (Reddy & Lokesh, 1994) and reactive nitrogen species (Sreejayan & Rao, 
1997; Unnikrishnan & Rao, 1995). It also inhibits lipid peroxidation in different 
animal models (Reddy & Lokesh, 1992; Sreejayan & Rao, 1994) and induces 
antioxidant and cytoprotective enzymes (Dinkova-Kostova & Talalay, 2008; 
Motterlini et al, 2000). For example, curcumin protectes against homocysteine-
induced oxidative stress, decreasing lipid peroxidation and improves learning and 
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memory process that is impaired by homocysteine (Ataie et al, 2010). Vascular 
endothelial cells treated with curcumin prevent oxidant mediated injury by 
increase heme oxygenase production (Motterlini et al, 2000). In addition to its 
direct ability to attenuate the reactivity of oxygen free radical species, curcumin 
may function indirectly as antioxidant by inhibiting the activity of inflammatory 
enzymes or by enhancing the synthesis of glutathione, the most important 
endogenous antioxidant (Piper et al, 1998). 
Several in vivo and in vitro studies reported the benefical effects of curcumin on 
the brain. For example, (Rajakumar & Rao, 1994) showed the curcumin inhibition 
of lipid peroxidation induced by ferrous ions, ferric ascorbate and ferric-ADP-
ascorbate in brain homogenates. Has been showed in the brain of ethanol 
intoxicated rats, a signiﬁcant curcumin-induced reversal of lipid peroxidation, and 
an enhancement of glutathione. Moreover, curcumin reduces oxidative damage on 
Alzheimer pathology. In fact curcumin inhibits amyloid beta oligomer formation 
(Yang et al, 2005). In animal models of Alzheimer's disease, dietary curcumin is 
effective in significantly lowering principal index of inflammation such as the 
proinflammatory cytokine IL-1β, GFAP, an astrocytic marker associated with 
injury and inflammatory processes and PT immunolabeling of microglia in 
cortical and hippocampal neuronal layers; reduces oxidative damage and 
decreases overall insoluble amyloid, soluble amyloid, and plaque burden 
(Frautschy et al, 2001; Lim et al, 2001; Pan et al, 2008). It is not known whether 
curcumin taken orally can cross the blood brain barrier or inhibit the progression 
of Alzheimer’s disease in humans. As a result of the promising findings in animal 
models, clinical trials of oral curcumin supplementation in patients with early 
Alzheimer’s disease are under way. The results of a 6-month trial in 27 patients 
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with Alzheimer's disease found that oral supplementation with up to 4 g/day of 
curcumin is safe (Baum et al, 2008). Recent studies have also shown that a diet 
with curcumin improves the inflammation associated with obesity and diabetes in 
a mouse model that shows obesity to insulin resistance as well as significantly 
reduced macrophage infiltration of adipose tissue, inflammatory and metabolic 
shifts prevent associated with obesity and improve glycemic control mouse 
models of diabetes type 2 (Weisberg et al, 2008). Is known that oxidative stress 
alters the neuronal function and plasticity after traumatic brain damage. Curcumin 
with its antioxidant activity reduces oxidative damage and normalizes the levels 
of BDNF and synapsin I, which is a phosphoprotein involved in the release of 
neurotransmitter, in stretching and maintenance of axonal synaptic contacts. Also 
normalizes the levels of CRE, a transcription factor involved in learning and 
memory and important modulator of gene expression induced by BDNF (Wu et 
al, 2006). Pretreatment of rat cortical neurons exposed to 10 μM glutamate for 24 
hours, with curcumin reversed the BDNF expression and cell viability in a dose- 
and time-dependent manner (Wang et al, 2008). Moreover Xu and colleagues 
investigated the effect of orally administered curcumin on behavior in a chronic 
stress model of depression in rats. This study suggests that the effects of chronic 
administration of curcumin on the behavior of chronic stressed rats may be related 
to the modulating effects of the dysfunction of the hypothalamic-pituitary-adrenal 
(HPA) axis, through selective increase in BDNF in the frontal cortex and the 
hippocampus of the rats (Xu et al, 2006). These results underscore the 
antidepressant effect of curcumin and its role in stress-related disorders. 
Interesting was the finding of Bishnoi that indicates the curcumin as a therapeutic 
drug for haloperidol-induced tardive dyskinesia. In particular in this hyperkinetic 
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movement disorder curcumin is able to decrease oxidative damage and improves 
stereotypic movements caused by alteration in catecolamine metabolism (Bishnoi 
et al, 2008).  
Has been demonstrate that curcumin is involved in chromatin remodeling, in 
particular in the suppression of histone acetylation. Li and colleagues 
hypothesized that this compound suppresses cardiac hypertrophy through the 
disruption of p300 histone acetyltransferase-dependent (p300-HAT dependent) 
transcriptional activation and downstream GATA4, NF-kappaB, and TGF-beta-
Smad signaling pathways (Li et al, 2008). 
It is also worth mentioning that given its activity on histone deacetylases (HDAC) 
(Chen et al, 2007), curcumin may be considered an epigenetic drug, this being of 
potential relevance in the absence of a correct MeCP2 based chromatin 
remodelling, like that found in the RTT patients. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
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In the classic form of Rett Syndrome, after a period of 6-8 months of apparently 
normal development, girls present a developmental arrest followed by a 
regression, with loss of speech and purposeful hand use accompanied by a 
reduction in interpersonal contact, stereotypic hand activities, EEG abnormalities 
and microcephaly. Other somatic and neurological symptoms include sleep 
disorder, muscular rigidity and cold and blue extremities to indicate peripheral 
circulation problems. It is not known whether RTT is associated to vascular 
abnormalities in peripheral microcirculation and dissecting the vascular function 
is feasible in human RTT patients. We have focused our studies on the vascular 
system functionality of MeCP2 null male mice at 50 days post birth, symptomatic 
MeCP2 heterozygous females and wild type littermates, using the pressured 
myograph system. Furthermore, since no effective pharmacological treatment is 
as yet available for this disorder, we investigated the effects of curcumin, a potent 
anti-oxidant and anti-inflammatory polyphenol with cardiovascular protective 
effects. We studied the effect of curcumin treatment on vascular functionality, 
molecular expression, behavior and motor activity of MeCP2 heterozygous adult 
females. They were included in this work because they have residual levels of 
MeCP2 with a mosaic expression due to the inactivation of the X chromosome, 
live longer than males, gradually over the time they develop motor deficits and 
stereotyped behaviors and for these phenotypic characteristics may be subject to 
complex behavioral tests. In Figure 17 is displayed this animals phenotype that is 
characterized by stereotypic behavior (crossing of the hind legs), abnormal 
breathing, tremors, changes in hair, hypoactivity, in contrast to wild-type animals, 
MeCP2 knockout if held by the tail show the reflection of placement of the legs. 
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Figure 17: Characteristic phenotype of Rett female mouse. 
 
 
 
  
 
 
 
 
 
 
 
 
MATERIALS AND 
METHODS  
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3.1 Animals and genotyping  
All experiments were carried out in accordance with the directives of Council of 
European Communities (86/609/EEC) and approved by Italian Ministry of Health 
for the care and use of laboratories. The animals used for experiments were 
derived from heterozygous B6.129SF1-MeCP2
tm1/Jae
 B6 knock-out females 
(MeCP2
+/−
) (Chen et al, 2001). The MeCP2
tm1/Jae
 male mice exhibit a significant 
loss of body weight, body tremor and shaking paw by the fifth week, while 
heterozygous mutant females seem normal for the first four months when begin to 
show pathological symptoms such as reduced activity, ataxic gait, piloerection, 
stereotyped movements and heavy breathing.  
Heterozygous females were originally crossed to C57BL6 for two generation, 
followed by breeding among offspring of the same generation with breeder 
changes and were maintained on a mixed background. Mixed background reduced 
mortality and was necessary to obtain the high numbers of mice required by 
extensive analysis. Age-matched littermates were used in all experiments to 
control for possible effects of genetic background unrelated to the MeCP2 
mutation (Boggio et al, 2010; Lonetti et al, 2010; Ricciardi et al, 2011). Mutant 
and wild-type mice were reared in standard condition: housed in polycarbonate 
cages with water and food available ad libitum. The experimental rooms were 
kept on a 12:12 light:dark cycle with lights on from 6:00 AM to 6:00 PM. 
Ambient temperature was maintained at 21°C. Mice were genotyped by PCR. 
DNA extracted from the biopsy of a small piece of tail taken to P10. MeCP2 
alleles identified by polymerase Chain Reaction (PCR) using two sets of primers. 
The first primer (5' primer: 5'-CAC CAC AGA AGT ACT ATG ATC) and the 
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second primer (3' primer: 3'-CTG ACA ATG AGC TTT CTT CTA) used to 
produce 250 bp to identify MeCP2 null allele. After amplification, the DNA left 
to run on 1,5% agarose gel electrophoresis containing ethidium bromide and 
examined under UV light to identify genotype. 
 
3.2 Curcumin treatment 
Six months old symptomatic MeCP2
+/−
 females as well as the age-matched wild-
type littermates were split into two equal and homogeneous experimental groups 
(five animals for each group) on the bases of age, weight, and coordination 
capability (Rotarod test). The curcumin treated animals were feed, for 21 days 
with 5% curcumin (5 g curcumin in 100 g pellets for rodents) and they weighed a 
time at week from the first day of treatment. The pellets were softened with a 
small amount of water so they can be unmade and added the appropriate 
percentage of turmeric powder. After that, with the help of a syringe, were 
reconstituted in their original form. The same procedure was also performed for 
the food of controls group. Water was provided ad libitum instead. The 
administration was performed every two days and each time has been marked the 
amount of food consumed and supplied to the two groups. All behavioural 
experiments were conducted during the treatments period and three weeks after 
animals were sacrificed and mesenteric artery, aorta, cerebral cortex and blood 
were extracted for molecular and functional experiments.  
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3.3 Pressure Myograph System 
The Pressure myograph system is used to measure the physiological function and 
properties of small arteries, veins and other vessels. In this system, vessels retain 
many of their in vivo characteristics. In pressure myography, an intact small 
segment of an artery or vein is mounted onto two small glass cannulae and 
pressurized to a suitable transmural pressure. This near physiological condition 
permits the investigation of intrinsic (myogenic) responses which can be 
extrapolated to the in vivo behaviour of the entire vascular bed (autoregulation). 
Both constriction and dilation can be readily measured as changes in diameter of 
the preparation via digital video edge-detection. Since intrinsic myogenic 
constriction is present, the role and function of the endothelium for this 
phenomenon can be studied. 
For reactivity experiments a third-order branch of the mesenteric arterial tree (≈2 
mm in length) was dissected and isolated using a stereo microscope. The vessel 
was mounted on two glass microcannule in a microvessel chamber and secured 
with a ligature (Figure 18). 
 
 
  
 
 
 
Figure 18: Representation of mouse third-order branch of mesenteric 
arterioles isolated and mounted on two glass microcannule. 
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The proximal cannula was connected to a pressure servo controller and the distal 
cannula was closed with a stopcock. The chamber was mounted on a stage of a 
microscope connected to a video camera and then to a personal computer 
equipped with a video dimensioning software. The vessel was visualized on the 
computer monitor and the internal diameter was measured by adjusting the guides 
superimposed by the software (Figure 19).  
 
Figure 19: Schematic representation of pressure myograph system. 
 
In our experiments, in particular, the vessels were equilibrated for 60 minutes 
under constant intraluminal pressure (45 mmHg) in warmed (37°C) and bubbled 
(95% air and 5% CO2) physiological salt solution, which contained NaCl 120 
mM, NaHCO3 25 mM, KCl 4.7 mM, KH2PO4 1.18 mM, MgSO4 1.18 mM, CaCl2 
2.5 mM, EDTA 0.026 mM, and glucose 5.5 mM (pH 7.4). Vessels were 
considered viable and used if they constricted ≈70% of their resting lumen 
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diameter in response to an extraluminal application of high-potassium (125 KCl 
mM) physiological salt solution containing 100 µM of noradrenaline (NA).  
In small arteries from all groups of animals, endothelium-dependent and -
independent relaxations were assessed by measuring the dilatory responses of 
mesenteric arteries to cumulative concentrations of acetylcholine (0.001-100 μM, 
Sigma Chemicals) and sodium nitroprusside (0.01-100 μM, Sigma), respectively, 
in vessels precontracted with norepinephrine (10 μM). To evaluate NO 
availability, a curve to acetylcholine was constructed after 30-min preincubation 
with the NOS inhibitor L-NAME (100 μM, Sigma). Finally, to evaluate the 
influence of ROS, acetylcholine was repeated after 30-min preincubation with the 
antioxidant ascorbic acid (100 μM, Sigma). 
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3.4 Determination of Superoxide Anion Production in the 
Mesenteric Vessels 
Dihydroethidium (DHE, Sigma) was used to detect superoxide anion production. 
This compound is a lipophilic cell-permeable dye that can be rapidly oxidized to a 
fluorescent marker product by O2
-
 produced within the cell. The fluorescent 
product intercalates with DNA and stains the cell nucleus red.  
Frozen mesenteric vessels were cut into 30-μm thick sections and placed on a 
glass slide. Three slides per segment were analyzed simultaneously after 
incubation with Krebs solution at 37°C for 30 minutes. Krebs-HEPES buffer 
containing 2 μM DHE was then applied to each section and incubated in a dark 
incubator at 37°C for 30 minutes. Ethidium fluorescence was detected with a 563-
nm long-pass filter after excitation at 543 nm, and images were obtained with a 
Zeiss LSM 510 confocal microscope equipped with a krypton/argon laser. The 
percentage of arterial wall area stained with the red signal was estimated using an 
imaging software (McBiophotonics Image J; National Institutes of Health, 
Bethesda, MD). All experiments were performed on duplicate. 
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3.5 Measurements of Plasma Malonyldialdehyde Levels  
Malondialdehyde is one of the several low molecular weight end products formed 
via the decomposition of certain primary and secondary lipid peroxidation 
products, it can be measured by reaction with thiobarbituric acid (Ohkawa et al, 
1979). The measurement of Thiobarbituric Acid Reactive Substances (TBARS) is 
a well-established method for screening of monitoring lipid peroxidation in 
several types of samples including human and animal tissues and fluids. The 
blood was obtained by cardiac puncture in presence of 0,5 M EDTA and then 
isolated by centrifugation at 3000 rpm for 5minutes, pipetted off the top yellow 
plasma layer without disturb the white buffy layer and freezed at -80°C until 
experiment time. The plasma samples will be stable for one month while stored al 
-80°C. Systemic lipid peroxidation was quantified by measuring plasma 
malonyldialdehyde (MDA) levels by commercial kit (Cayman Chemical). The 
MDA-TBA adduct performed by the reaction of MDA and TBA under high 
temperature (90-100°C) and acidic conditions is measured colorimetrically. In 
particular, each sample (100 µl) was added with the same volume of SDS Solution 
and 4 ml Colour Reagent. The vials were boiled in water for one hour and then 
immediately place in ice bath to stop the reaction. After 10 minutes, vials were 
centrifuged for 10 minutes at 1600 g at 4°C. 150µl of each sample was loaded in 
the plate and read the absorbance at 530-540 nm. In this assay, an MDA standard 
is used to construct a standard curve against which unknown samples can be 
plotted. 
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3.6 RNA extraction and Real Time PCR  
Expression of mRNA for eNOS and iNOS was assessed by Real Time PCR. Total 
RNA was isolated from mesenteric vessels, aorta and cerebral cortex with Tripure 
Isolation Reagent (Roche Molecular Biochemicals). Briefly, 1 ml Tripure 
Isolation Reagent was added to tissue and then homogenized. Each homogenized 
sample was added with 0.2 ml of chloroform, shaked vigorously and incubated for 
15 minutes at room temperature. To separate the solution in three phases 
(colorless aqueous phase containing RNA, white interphase and red organic phase 
containing protein and DNA; Figure 20) samples were centrifuged at 12000g for 
15 minutes at 4°C. To precipitate the RNA the colorless aqueous phase was 
transferred in a new centrifuge tube and added with 0,5 ml isopropanol, mixed 
and centrifugated at 12000 g for 10 minutes at 4°C. The supernatant was 
discarded and pellet washed with 75% ethanol. Finally the RNA pellet was 
resuspended in diethylpyrocarbonate (DEPC)-trated RNase free water and 
incubated for 10 minutes at 55°C. 
 
Figure 20: Representative diagram of the three 
phases of the solution: upper colorless aqueous 
phase contains RNA; white interphase and 
lower red organic phase contain DNA and 
protein. 
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The RNA was quantified by spectrophotometry and 1 µg used for the synthesis of 
first-strand cDNA trough High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) as shown below. 
 
Component 
Volume/Reaction 
(µl) 
Thermal cycling 
condictions 
10X RT Buffer 2.0 
Step 1 : 25°C  10 min 
Step 2: 37°C 120 min 
Step 3: 85°C    5 sec 
Step 4: 4°C     ∞ 
25X dNTP Mix (100mM) 0.8 
10X RT Random 
Primers 
2.0 
MultiScribe Reverse 
Transcriptase 
1.0 
Nuclease-free H2O 4.2 
Total per Reaction 10.0 
 
The reaction of quantitative real-time PCR was performed, on a rate equal to 1/10 
of the RT reaction product, using Taqman Gene Expression Assays (Applied 
Biosystems) and the "delta-delta Ct" method. Sequences targeted by fluorescent 
probes were endothelial nitric oxide synthase (eNOS; Mm00435204_m1; Applied 
Biosystems) and inducible nitric oxide synthase (iNOS; Mm00440485_m1; 
Applied Biosystems) and the probe against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Mm 99999915_g1; Applied Biosystems) as 
housekeeping gene. The PCR conditions included 50°C for 2 min, 95°C for 10 
min, followed by 40 cycles of 95°C for 15s 60°C for 1 min. 
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3.7 Immunostaining of eNOS  
Small mesenteric arteries were immediately fixed in cold 4% paraformaldehyde 
after collection from small bowel loops and paraffin embedded at 56°C. Eight-
micron-thick sections were serially mounted on glasses and sequentially treated as 
follows: 1% hydrogen peroxide in methanol for 30 minutes; microwave antigen 
retrieval (600 W in 10 mmol/L of sodium citrate; pH 6.0); normal goat serum 
(1:20; Dakopatts Glostrup, Denmark), rabbit anti-eNOS polyclonal antibody (sc-
654, 1:100 overnight at 4°C, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 
biotinylated anti-rabbit immunoglobulins, peroxidase-labeled streptavidin 
complex (Vector Laboratories, Burlingame California), 3,3-diaminobenzidine 
tetra-hydrochloride (DAB; Amresco, Solon, OH, USA), hematoxylin 
counterstaining. Negative controls were obtained by substituting the primary 
antibody with preimmune rabbit serum. Endogenous peroxidases and avidin-
binding activity were assayed by incubating slides with DAB alone or with 
peroxidase-labeled streptavidin complex/DAB, respectively as previously 
reported (Virdis et al, 2007). 
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3.8 Rotating rod test (Rotarod) 
The rotarod has been used to assess the ability of animals to balance on a rotating 
rod. As the speed of rotation was increased, it became more difficult for the 
animal to keep its balance. We tested the time it took the animal to fall under 
continuous acceleration from 4 to 40 rpm. The latency to fall off the rotating rod 
was used as an indication of motor coordination and balance. The experimental 
apparatus consisted of a rotating drum whose surface was manufactured to 
provide optimal grip for the animal. Separating disk divided the drum into five 
separate exercise lanes each suited for an individual animal (Figure 21). The 
mouse dropped onto the individual sensing platform below and the instrument 
automatically recorded the amount of time spent on the drum.Treated and 
untreated animals (Rett and wild-type) were tested before and after curcumin 
administration on rotarod apparatus. Mice performed five trials per day allowing a 
5 minutes inter-trial interval. To habituate, mice have been transferred, in their 
home cages, from the holding room to the experimental room 30 minutes before 
the experimental section start. 
 
 
 
 
 
 
Figure 21: Schematic Rotarod 
experimental apparatus. 
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3.9 Behavioural observation 
To test whether curcumin treatment caused behavioral changes in wild-type and 
RTT mice, they were divided into two groups and one was administered with the 
drug. Before and after treatment, at three different times of the day (morning 9 
am, afternoon 1 pm and evening 6 pm) the animals were recorded with a camera 
in their cages. Each test session lasted two hours and the duration time of 
stereotyped movements (repetitive and involuntary movements that animals make, 
especially with the front legs, scratching the back up to injuring) and resting time 
(the time that the animals are sleeping or not moving) were measured. Cages were 
placed in the test room at least half an hour before the experiment so that the 
animals were not stressed in the new environment.  
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3.10 Open Field test 
The open field test is a simple assessment used to determine general activity 
levels, gross locomotor activity and exploration habits in mice. It is based on the 
natural tendency of an animal to explore and avoidance reaction to protect itself, 
which make normal animals to spend more time in the corners and the periphery 
than in the centre (the most anxiogenic area).  
The apparatus consisted of an arena square (60 x 60 x 30 cm) with transparent 
vinyl flooring material (lexan) and black walls. Under the floor there was a white 
card which was drawn a square (30 x 30 cm) at the center of the arena (Figure 22). 
The arena was connected to a camera that reproduced on a computer monitor the 
image of the apparatus.  
 
 
Figure 22: Open Field arena square used for testing anxiety and exploratory 
drive. 
 
The acquisition of the tracks was through a video tracking system Noldus 
(Ethovision XT, Wageningen, The Netherlands) that allowed the inclusion of 
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variables experimental (eg. name, treatment, sex, age, genotype). The system was 
able virtually to divide the arena into a "center" (center of the arena), a 
"periphery" (portion of the space between the edge of the arena and the central 
square), the "corners" (corners of the arena) and the "central point" (point located 
at the exact center arena) and to identify some parameters that allowed the 
program to consider the animal as the object of interest. Parameters recorded 
were: distance travelled in the whole arena and in the central and peripheral zones; 
percentage of time spent in the central zone and in peripheral zones; duration of 
the immobility (resting time in seconds) in the whole arena, in the periphery and 
in the center; number of entries in the central zone; latency to entry into the 
central zone. 
Testing was conducted during the light phase of the cycle and the animals were 
transported in their cages and left undisturbed for 30 minutes before the test.  
The apparatus cleaned with 10% alcohol and allowed time for it to dry. Each 
mouse was placed in the middle of a peripheral zone of the arena facing the wall 
and allowed to explore freely the apparatus for 5 minutes, with the experimenter 
out of the animal’s sight. At the end of the run, animals were put back into their 
home cage. After each run, any faeces were removed and the arena was 
thoroughly wiped (water then alcohol 10 %). Indices of anxiety in animals were: 
decreased locomotor activity (basal locomotion), decreased stay at the center and 
increased anxiety behaviours such as defecation. The only time spent in the center 
could be used as a preliminary indication of anxiety: very anxious mice tend to 
avoid the center of the arena. The total activity tends to decrease over time and 
this is considered a measure habit of novelty apparatus. 
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3.11 Data Analysis 
Results are presented as mean±SEM and analyzed by Student’s t test or two-way 
repeated measures ANOVA where appropriate.  
Data were analyzed using GraphPad 5 analysis software. The unpaired Student’s t 
test used to make comparisons between groups used. The significance of the 
effects of factors and the differences between samples were estimated by analysis 
of variance (two-way repeated measures ANOVA). Data are presented as mean ± 
SEM and a value of P<0.05 was considered statistically significant. 
 
  
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 66 
4.1 Vascular reactivity on WT and Rett mice  
A third-order branch of the mesenteric arterial tree was dissected and isolated 
using a stereo microscope. The vessel was mounted on two glass microcannule in 
a microvessel chamber and the mesenteric vessel resistance was investigated with 
pressurized myograph.  
In mesenteric vessels from the WT group, the relaxation to increasing 
concentration of acetylcholine was preserved. This was significantly attenuated by 
L-NAME (a NOS inhibitor) and not affected by the antioxidant ascorbic acid 
(Figures 23A and 24).  
On the contrary, vessels from MeCP2
+/−
 female mice showed a significant 
(P<0.001) attenuated relaxation to acetylcholine. In this group, the inhibitory 
effect of L-NAME on relaxation to acetylcholine, although still evident at the 
maximal dose, was significantly blunted (Figures 23B and 24). In addition, 
ascorbic acid potentiated the relaxation to acetylcholine and restored the 
inhibitory effect of L-NAME (Figure 23B).  
Investigating the mesenteric vessel resistance from MeCP2
y/−
 male mice we 
evidenced as they were characterized by a further reduced relaxation to 
acetylcholine as compared to MeCP2
+/−
 female mice (P<0.05), which was totally 
resistant to L-NAME. Ascorbic acid only in part enhanced the relaxation to 
acetylcholine and restored the inhibition by L-NAME (Figure 23C).  
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A B 
C Figure 23: Endothelium-dependent 
relaxations elicited by Acetylcholine 
in mesenteric resistance arteries 
without (saline) or with L-NAME or 
Vit C from WT female (A), Rett 
female (B) and P50 Rett male mice 
(C). Each point represents the mean 
of 6 experiments ± SEM. *P<0.05, 
**P<0.01. 
 
 
Figure 24: Inhibition by L-
NAME on maximal response to 
acetylcholine in vessels from 
WT, MeCP2
+/−
, and curcumin-
treated MeCP2
+/− 
mice, without 
(saline) or with ascorbic (asc) 
acid. Results are given as the 
mean of 6 experiments ± SEM. 
*P<0.05, **P<0.01. 
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At the same time, to test the endothelium-independent relaxation we incubated the 
mesenteric vessels of each group with sodium nitroprusside, and we found that the 
relaxation to this compound was similar in WT and MeCP2
+/− 
animals (Emax: 
97.2±0.8% and 97.8±0.9%, respectively), but it was significantly attenuated in 
MeCP2
y/−
 mice (Emax: 80.4±1.1%; P<0.01 vs other groups) (Figure 25). 
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Figure 25: Vasorelaxation endothelium independent. Vascular response 
to increasing concentrations of sodium nitroprusside in WT and Rett 
female and male mice. **P<0.01. 
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4.2 Endothelial function: effect of curcumin  
Rett female mice and wild type littermates were treated 21 days with curcumin 
5% (w/w) in the diet.  
After this period vascular functionality study highlighted that curcumin treatment 
dramatically potentiated, but nor normalized, the relaxation to acetylcholine in 
mesenteric vessels from MeCP2
+/−
 mice, and restored the inhibitory effect of L-
NAME on acetylcholine-induced relaxation (Figure 25). In such arteries, the 
vascular response to acetylcholine was no longer affected by ascorbic acid (Figure 
26).  
On the contrary, in vessels from WT mice, curcumin administration did not 
modify the relaxation to acetylcholine (Emax: 97.2±0.6%), the effect of ascorbic 
acid (Emax: 96.4±0.6%), or the inhibitory effect of L-NAME on acetylcholine 
(Emax: 58.3±0.9%; inhibition: -38.9±0.7%) were null.  
Relaxations to sodium nitroprusside were not modified by curcumin 
administration in MeCP2
+/− 
and WT (Emax: 97.2±0.8% and 97.8±0.9%, 
respectively).  
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Figure 26: Endothelium-
dependent relaxations elicited 
by Acetylcholine in mesenteric 
resistance arteries from Rett 
control (A) and curcumin 
treated (B) female mice without 
(saline) or with L-NAME or Vit 
C. Each point represents the 
mean of 6 experiments ± SEM. 
**P<0.01. 
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4.3 Vascular superoxide generation: effect of curcumin  
The vascular superoxide generation has been evidenced through dihydroethidium 
(DHE) staining. DHE is rapidly oxidized to a fluorescent product by O2
-
 produced 
within the cells, intercalates with DNA and stains the cell nucleus red.  
In small arteries from MeCP2
+/−
 mice, DHE analysis revealed a dramatic increase 
in superoxide anion production, as compared with WT (Figure 27). The enhanced 
superoxide generation was abrogated by curcumin (Figure 27).  
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Figure 27: Representative DHE staining and quantification (bar graph) of 
the red signal  in mesenteric arteries (magnification X 40) from WT and 
MeCP2
+/−
 mice feed with or without curcumin. Results are given as the mean 
of 6 experiments ± SEM. *P<0.05, **P<0.01. 
 71 
4.4 Plasma MDA levels: effect of curcumin  
Malondialdehyde (MDA) is a biomarker of lipid peroxidation and an indicator of 
oxidative stress. We collected mice blood and separated plasma fraction by 
centrifugation. We tested the malondialdehyde levels in the plasma of WT, Rett 
and curcumin treated animals.  
The comparison of malondialdehyde values measured within Rett and WT mice 
has shown that at baseline, Rett mice displayed high MDA levels. The statistical 
analysis shows a significant difference between the two groups. Curcumin 
administration is able to significantly reduce levels of malondialdehyde (Figure 
28).  
 
 
 
 
 
 
 
 
Figure 28: Oxidative stress parameter MDA. Mean±SEM Malondialdehyde 
(MDA) in the plasma of WT and MeCP2
+/−
 mice feed with or without 
curcumin. **P<0.01.  
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4.5 eNOS expression in mesenteric vessel and aorta 
The eNOS mRNA expression was measured by quantitative RT-PCR in 
mesenteric vessels and aorta of Rett animals, wild type age-matched littermates 
and curcumin treated. Consistently with the functional experiments on mesenteric 
vessels the Real Time-PCR provided the evidence that Rett mice have decreased 
levels for eNOS mRNA expression in the mesenteric arterioles and aorta (Figure 
29).  
The curcumin treatment restored the expression level of eNOS up to the levels of 
wild type animals. The same not happen in the aorta in which curcumin fails to 
increase levels of eNOS (Figure 29). 
 
 
 
 
 
 
Figure 29: Quantitative RT–PCR analysis of mRNA expression for eNOS in 
Mesenteric vessels (A) and Aorta (B) of Wild-Type and Rett animals treated 
or not three weeks with 5% curcumin. eNOS has been normalized to the 
expression of GAPDH. Data represent the mean±SEM (*P<0.05, **P<0.01). 
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4.6 Vascular eNOS immunostaining 
Immunostaining for eNOS protein confirms the date found in molecular analysis. 
High eNOS levels were constitutively and specifically present in endothelial cells 
of small mesenteric arterioles from WT mice (Figure 29). On the contrary, all 
MeCP2
+/−
 animals displayed only a faint eNOS immunostaining at level of the 
outer vascular smooth muscle cells but no appreciable amounts of eNOS in the 
endothelium (Figure 30). 
 
  
Figure 30: Representative photomicrograph of  immunostaining for eNOS in 
small mesenteric arteries from WT and MeCP2
+/−
 mice. A strong, specific 
eNOS staining is detected in endothelium of control vessels, while mesenteric 
arterioles from MeCP2
+/−
 mice show only a slight eNOS immunostaining at 
level of the outer vascular smooth muscle cells, without any appreciable 
amount in the endothelial cell layer.  
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4.7 Body weight variation 
During the 21 days of curcumin treatment the body weight of all animals was 
monitored. WT control and treated mice have a similar trend: they increase their 
weight day by day. MeCP2
+/- 
have a constant weight for 14 days, then begin to 
fall. Instead, MECP2
+/-
 curcumin treated animals increase significantly their body 
weight in the first two weeks and decrease dramatically in the last phase of 
treatment (Figure 31). 
 
 
 
 
 
 
 
 
 
 
Figure 31: Curcumin effect on the animal weight, normalized at 1.0. 
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4.8 Rotarod test 
To analyze the motor coordination learning and memory at the treatment end all 
animals performed the rotarod test. In this motor test the latency to fall off the 
rotating rod was used as an indicator of motor coordination and balance. In our 
experiments, no significant differences were observed between treated and 
untreated animals, but we can see a trend in which treated animals can best 
accomplish the motor task than untreated ones (Figure 32). 
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Figure 32: The averages (±SEM) for time spent on rotarod across five test 
trials for MeCP2
+/-
 mice curcumin treated and untreated. 
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4.9 Stereotyped movements: effect of curcumin  
Before the sacrifice, treated and untreated Rett mice and wild type age-matched 
littermates were recorded for two hours at three different times of the day 
(morning, afternoon and evening). The movies were analyzed for two behavioral 
parameters:  
1. resting time; 
2.  stereotyped movements.  
 
The observation demonstrated that MECP2
+/-
 curcumin treated animal spent much 
less time making stereotyped movements (repeatedly and sometimes 
compulsively scratched the back especially with the hind limbs) than controls and 
spent more time to rest and sleep (Figure 33 A and B).  
 
 
 
 
 
 
Figure 33: Behavioral observation. Percentage of time spent to perform 
stereotyped movements (A) and to rest or sleep (B) by Wild-Type and Rett 
female mice untreated (ctrl) and treated with 5% curcumin (curc). Data 
represent the mean±SEM (*P<0.05, ***P<0.001). 
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4.10 Open Field test 
To assess the emotional behavior we subjected Rett and WT females to the Open 
field test. The test exploits the natural propensity of the animal and exploratory 
features such as the size of the arena, the level of lighting and background noise 
that can accentuate the aversion which the animal feeds to the instrument 
indicating how much the experimental condition has anxiety characteristics and 
allows the detection of many parameters such as the locomotor activity, 
exploratory activity, anxiety and fear. Figure 34 shows the time each animal 
spends at the center of the arena and near is indicated to the average for each 
group. Data analysis by comparing the averages of two groups, finds no 
significant differences in time spent in the center of the arena (Mann-Whitney test, 
p 0.690). 
 
Figure 34: Time in seconds spent in the "center" of the arena for each animal 
in each group. In addition to individual scores shows the average for the 
treated group (n = 5) and controls (n = 5) with SEM. 
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The other parameter analyzed was the time spent in the corners of the arena 
(Figure 35): anxiety and fear lead the animal to stay more in the corners. Data 
analysis by comparing the averages of two groups, finds no significant differences 
in time spent in the corner of the arena (Mann-Whitney test, p 1,000). 
 
Figure 35: Time spent in the "corners" of the arena for each animal in each 
group. In addition to individual scores shows the average for the treated 
group (n = 5) and for controls (n = 5) with SEM. 
 
The last parameter considered in this test is the percentage of time spent moving 
in the arena. There is no significant difference in the total time spent moving for 
the two groups (Mann-Whitney test, p = 0.151) (Figure 36). 
 
Figure 36: Percentage of time spent moving for each animal in each group. 
The bars indicate SEM. 
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All animals have explored the apparatus, probably moving in different areas, 
depending on the subjective appetite or not to go in the middle of it. Figure 37 
shows two tracks of the run of treated and control animals. 
 
 
 
 
 
 
 
Figure 37: Example of a path drawn by an curcumin treated animal (A) and 
a control one (B). The red line indicates the route taken by the animals. 
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DISCUSSION 
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Rett Syndrome is a neurodevelopmental disorder described for the first time in 
1966 by the Austrian neurologist Andreas Rett. More than 40 years of research led 
to the discovery that RTT is caused by mutations in a specific gene: MeCP2. The 
discovery that RTT is a monogenic disease is particularly important to understand 
the physiopathology of the syndrome and to shed light on the causes of autism 
spectrum disorders. More than 300 associated mutations have been identified and 
clinical trials have been focused on drugs to enhance the quality of life for those 
affected. Also, scientists have made significant progress with animal studies, 
including effectively reversing symptoms of the disorder. The prominent CNS 
effects of the RTT syndrome have so far directed a major research effort into the 
investigation of alterations taking place in the central nervous system, almost 
neglecting the other somatic peripheral symptoms (Stearns et al, 2007). Some 
authors investigated the cardiovascular functions in human patients and in RTT 
animal models, given that  they believe that the 26% of  sudden deaths may be 
due to abnormalities in the autonomic regulation of hearth rate (Bissonnette et al, 
2007). Moreover the frequent peripheral circulation problems of RTT patients are 
poorly investigated. Only in 1997 Bjure and colleagues described abnormalities in 
the blood flow in the brain of RTT girls (Bjure et al, 1997).  
In our studies we investigated for the first time the peripheral microcirculation in 
a symptomatic MeCP2 knockout mouse model to understand the causes of 
vascular dysfunction  and  to suggest an effective therapeutic treatment  able to 
counteract the peripheral symptoms.  
In the first set of experiments, to investigate the function of the peripheral 
microcirculation in the symptomatic MeCP2 knockout mouse, we used the 
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pressurized myograph system to study the mesenteric arterioles vascular reactivity 
in wild type animals and in young MeCP2
y/-
 male and in adult MeCP2
+/-
 female 
mice. Subsequently we evaluated the impact of curcumin administration on 
vascular function and on properly chosen behaviuoral parameters in our female 
RTT mouse model.  
The first major finding of our study concerns the demonstration of endothelial 
dysfunction and the major mechanisms responsible for this alteration in RTT male 
and female animal model. In the mesenteric arterioles of the MeCP2
+/-
 mice, we 
observed a reduction in the vascular response to acetylcholine, an endothelium-
dependent vasodilator, together with a preserved relaxation to sodium 
nitroprusside, a direct smooth muscle cell relaxant compound, thus demonstrating 
the presence of endothelial dysfunction in such animal model of disease. To 
assess NO availability and oxidative stress, we used L-NAME and ascorbic acid, 
respectively. In MECP2
+/-
 mice, the inhibitory effect exerted by L-NAME on 
acetylcholine responses was significantly lower compared with that observed in 
controls, indicating reduced NO availability. Ascorbic acid improved the response 
to acetylcholine, suggesting that ROS generation contributes to endothelial 
dysfunction which characterizes such disease. Taken together, these findings 
indicate that ROS generation represents a major mechanism accounting for 
endothelial dysfunction in peripheral microcirculation of MeCP2
+/-
 mice, resulting 
in NO breakdown.  
The results are more dramatic in mesenteric vessels of MeCP2
y/-
 in which we 
evidenced that the NO availability is almost absent: the relaxation in the response 
to acetylcholine was totally refractory to L-NAME, while ascorbic acid only 
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slightly restored the inhibitory effect of L-NAME. This suggests a quite 
irreversible exhaustion of the L-arginine-NO pathway. In these animals also 
emerged a significantly reduced relaxation to sodium nitroprusside, demonstrating 
that the deletion of MeCP2 alters the endothelium functionality but involves also 
the underlying smooth muscle cells.  
In line with these functional data, MeCP2
+/-
 mice showed an increased 
intravascular superoxide anion generation and displayed higher plasma values of 
MDA, a systemic marker of oxidative stress. Our results in rodent agree with data 
in humans reporting the presence of systemic oxidative stress in RTT patients, in 
particular Sierra and De Felice reported elevated plasma levels of oxidative stress, 
decreased superoxide dismutase activity, and increased markers of lipid 
peroxidation. This is an intriguing and long debated aspect in Rett syndrome 
pathogenesis (De Felice et al, 2009; Sierra et al, 2001). Moreover the central 
nervous system is particularly sensitive to the adverse effects of oxidative stress as 
demonstrated in several nervous system pathologies (Atmaca et al, 2004). 
The major role of ROS in determining NO-related endothelial dysfunction in 
MECP2
+/-
 mice is in strict relationship with the second novel finding of our study, 
which deals with the vascular beneficial effect of curcumin. Indeed, vessels from 
curcumin treated MECP2
+/-
 mice showed an increased relaxation to acetylcholine, 
which became sensitive to L-NAME, while ascorbic acid was no longer able to 
affect the response to acetylcholine.  
The discovery that with curcumin L-NAME can inhibit relaxation to 
acetylcholine, an effect not exerted under baseline conditions, implies that NO 
availability is restored after pharmacological treatment. It is worth of noting that, 
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after curcumin administration, the restored inhibiting effect of L-NAME on 
acetylcholine was similar to what observed by ascorbic acid at baseline. 
Therefore, these findings suggest that the mechanism responsible for the 
beneficial effect of curcumin is probably specific and related to its antioxidant 
properties. This possibility is strengthened by the finding that curcumin also 
prevented the intravascular superoxide excess, and normalized the increased 
plasma levels of MDA, which resulted no longer different from controls.  
Our findings extend to the peripheral microcirculation of MECP2
+/-
 mice previous 
evidence showing the beneficial antioxidant properties of curcumin on other 
animal models affected by oxidative damage (Majithiya & Balaraman, 2005; 
Sompamit et al, 2009).  
Any way in the presence of ascorbic acid, either the relaxing effect of 
acetylcholine or the inhibitory effect of L-NAME on acetylcholine, although 
significantly improved, but not reach normal values. Thus, we cannot exclude that 
other ROS-independent mechanisms may contribute to endothelial dysfunction in 
MeCP2 knockout mice.  
Rett syndrome and its symptomatology are intimately connected to the 
uncorrected interpretation of chromatin epigenetic modification (acetylation-
methylation) caused by mutated or abnormal expression of MeCP2 (Agarwal et al, 
2011). Intriguingly, several reports indicated the chromatin structure and the 
epigenetic modifications as key determinants for eNOS expression. MeCP2 
protein has in fact been repeatedly localized bound to eNOS promoter and 
chromatin structure as well as chromatin modification (methylation and histone 
acetylation) are critical to the cell-specific expression of eNOS (Chan et al, 2004). 
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This context is consistent with MeCP2 playing an upstream action on eNOS 
expression and consequently on the levels of NO. In fact what we observed in 
histochemical assay from mesenteric vessels of MeCP2+/- mice was an abnormal 
expression of eNOS peptide in vascular smooth muscle cells, and any expression 
in endothelial cells. This lasting finding requires further experiments to be 
explained, but we can suppose the involvement of MeCP2 in the regulation of 
expression of eNOS. In line with the reduced NO availability herein reported, we 
found decreased eNOS mRNA expression in mesenteric vessels and in aorta of 
the MeCP2 deficient mice. We confirmed the reduction of eNOS expression also 
at protein level, indeed the immunostaining on isolated mesenteric vessel 
demonstrated that in the MeCP2
+/-
 animals eNOS protein is totally absent in 
endothelium respect with WT littermates in which the protein is specifically 
expressed in this vascular compartment. There is the possibility that the MECP2 
mutation leads to an incomplete eNOS expression, with a consequent reduced 
production and release of NO. This alteration might contribute to the reduced NO 
availability occurring in our MeCP2
+/−
 female mice, independently of increased 
ROS generation. Another possibility, not necessarily alternative, highlights eNOS 
as a putative intravascular source of ROS. This because the low eNOS expression 
might result by a deficiency of the substrate arginine or the cofactor 
tetrahydrobiopterin. This process, called “NOS uncoupling”, implies that the 
physiological activity of the enzyme for NO production is decreased and switched 
to the NOS-dependent ROS generation (Verhaar et al, 2004). To substantiate this 
conjecture, we documented a normalization of eNOS mRNA expression in 
mesenteric vessels but not in aorta from curcumin-treated MeCP2 animals, thus 
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suggesting that in a condition of ROS scavenging, such as that occurring under 
curcumin therapy, eNOS is switched back to its physiological function to generate 
NO in mesenteric district but not in regions distant from the absorption site. We 
recognize these as speculative hypothesis which needs future confirmations.  
Our findings may have clinical relevance. It is widely recognized that in 
physiological conditions, vascular NO not only causes vasodilation, but also 
protects the vessel wall against the development of atherosclerosis (Davignon & 
Ganz, 2004). In contrast, the impaired NO activity and the enhanced activity of 
vasoconstrictors, including ROS, are responsible for impaired vasodilator 
capacity. The imbalance of this equilibrium towards oxidative stress, beyond the 
altered vasomotricity, also initiates a variety of active processes, such as 
inflammation, cell migration and proliferation, relevant for the endothelial surface 
and adjacent cells. For these reasons, the altered NO-mediated endothelial 
function and the increased ROS generation which characterize the peripheral 
microcirculation of MeCP2 knockout animals, might have a causal relationship 
with the poor circulation, present in the extremities of RTT patients, including 
cold and cyanotic legs. 
The present study suggests curcumin as a promising medication to treat some 
symptoms of the Rett syndrome. The implementation of curcumin as a therapy to 
improve vascular system-related symptoms of the RTT syndrome needs to face 
some drawbacks that are outlined below. The main disadvantages of curcumin 
oral administration is its poor bioavailability, as it is principally accumulated in 
gastrointestinal tissues and metabolized in the liver Garcea and colleagues 
demonstrated that following the oral administration of 3.6 g/d curcumin for seven 
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days in colorectal cancer patients, curcumin is detectable in peripheral circulation 
(Garcea et al, 2005). In our system the proximity of the mesenteric vascular 
system to the intestine could be the reason of the striking action of curcumin, and 
indeed represents a proof of principle of its action on RTT mice vessels. Further 
studies are needed to optimize curcumin administration method. 
The adult MeCP2
tm1/Jae
 animal similarly to RTT patient develops typical 
stereotyped movements (Stearns et al, 2007). This behavioral aspect to date 
without any effective pharmacological therapy is often injurious and the girls are 
forced to wear gloves to avoid severe self-damage. Oxidative stress and 
stereotypic movements association is indeed well supported by a growing body of 
evidence in different animal models and for example in patients affected by 
obsessive compulsive disorders (Ghanizadeh, 2011; Guldenpfennig et al, 2011; 
Izzo et al, 2005). Specifically Bishnoi and colleagues assayed in rat animal model 
the benefical antioxidant effect of curcumin on central nervous system and on 
stereotyped movements (Bishnoi et al, 2008). In this scenario the curcumin 
benefical effect assayed by movie recording is not surprising. Our results on 
behavioural tests reported that curcumin administration is able to improve 
stereotyped movements and resting time but we not evidenced significant changes 
in emotional behavior and only an improvement trend of motor deficit. The 
increase of body weight in the first two weeks of treatment indicates that 
curcumin counteracts the RTT patients gastrointestinal problems that lead to the 
underweight tendency. 
In conclusion, the present study indicates that mesenteric vessels from MeCP2
+/−
 
female mice are characterized by an altered endothelium-dependent relaxation 
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caused by a reduced NO availability due to an increased ROS generation, and by a 
lower endothelial eNOS expression. These alterations, as well as the pathological 
stereotyped movements that characterize pathological animals, were reversed by 
curcumin administration. These data revealed that the RTT animal model shares 
some of the components of the clinical oxidative and vascular impairment of RTT 
patients, who often present circulatory problems that become increasingly severe 
in adulthood. It is proposed that the peripheral vascular system of these animals 
may be a source of excessive free radicals contributing to the local and systemic 
oxidative stress, and that curcumin based therapy may at least partly improve RTT 
symptoms derived from these redox alterations. 
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